Bazedoxifene: Comprehensive Research Paper on Hormone Replacement Therapy

Table of Contents

1. Summary
2. Mechanism of Action
3. Indications and Usage
4. Dosing and Administration
5. Pharmacokinetics
6. Side Effects and Adverse Reactions
7. Drug Interactions
8. Contraindications
9. Special Populations
10. Monitoring Requirements
11. Cost and Accessibility
12. Clinical Evidence and Efficacy
13. Comparison to Alternative Treatments
14. Storage and Handling
15. Goal Archetype Integration
16. Age-Stratified Dosing
17. Bloodwork Impact
18. Protocol Integration
19. References

1. Summary

Bazedoxifene is a third-generation selective estrogen receptor modulator (SERM) used in combination with conjugated estrogens for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis in women with an intact uterus. Bazedoxifene is a novel, non-steroidal, indole-based SERM developed using raloxifene as a template with the benzothiophene core substituted by an indole ring.

FDA Approval History:

On October 3, 2013, bazedoxifene received FDA approval as part of the combination drug DUAVEE (bazedoxifene and conjugated estrogens). Importantly, bazedoxifene as monotherapy (brand name Viviant) is not FDA approved in the United States, though it is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy.

Key Characteristics:

• Drug Class: Third-generation selective estrogen receptor modulator (SERM)
• Brand Name: Duavee (combination product)
• Combination Components: Bazedoxifene 20 mg + conjugated estrogens 0.45 mg per tablet
• Generic Availability: No (brand-name only as of 2025)
• Route of Administration: Oral tablet
• Standard Dose: One tablet once daily
• Typical Cost (Brand): $99-248 per month (with GoodRx discount)
• Typical Cost (Without Discount): ~$248 per month (retail)

Unique Mechanism as a Third-Generation SERM:

Bazedoxifene binds to both ERα (IC50 23 ± 15 nM) and ERβ (IC50 89 ± 159 nM) with high affinity. Bazedoxifene's mode of action varies depending on the targeted tissue or estrogen receptor:

• In breast and uterine tissue: Acts as a competitive antagonist, yielding antiproliferative effects
• In bone and lipid metabolism: Acts as an agonist by stimulating lipid metabolism and ensuring proper regulation of bone turnover

The Critical Difference from Earlier SERMs:

The clinically decisive difference among these drugs is their endometrial safety:

• Tamoxifen: Can act as an agonist for uterus endometrial hyperplasia and polyp production
• Raloxifene: Anti-estrogen effect on the uterus
• Bazedoxifene: Has been found to have no net effect on endometrial cancer occurrence and does not increase its risk

Bazedoxifene exhibits estrogen antagonistic effects on the endometrium when given alone and concomitantly with conjugated estrogens, with no substantial effect on endometrial thickness or endometrial hyperplasia.

Primary Indications (FDA-Approved in Combination with Conjugated Estrogens):

1. Treatment of moderate-to-severe vasomotor symptoms associated with menopause in postmenopausal women with an intact uterus
2. Prevention of postmenopausal osteoporosis in women with an intact uterus

Key Clinical Trial Evidence:

SMART Trial Program (Selective estrogens, Menopause, And Response to Therapy):

The approval was based on the SMART Phase III clinical trial program, which demonstrated:

Vertebral Fracture Reduction: In a 3-year trial with 6,847 subjects, bazedoxifene 20 mg and 40 mg reduced new vertebral fractures by 42% and 37% respectively compared to placebo, with incidence rates of 2.3% and 2.5% versus 4.1% for placebo.

Long-term Efficacy (5 years): At 5 years, bazedoxifene 20 mg and 40/20 mg showed relative risk reductions of 35% and 40% for new vertebral fractures versus placebo (4.5% and 3.9% vs 6.8%).

Endometrial Safety: At 12 months, endometrial hyperplasia incidence was low (<1%) and similar among treatment groups.

Vasomotor Symptom Relief:

When combined with conjugated estrogens, bazedoxifene effectively treats moderate-to-severe hot flashes while the bazedoxifene component protects the endometrium from estrogen-induced hyperplasia, eliminating the need for progestin therapy.

Important Warnings:

• Venous Thromboembolism (VTE): Increased risk of deep vein thrombosis and pulmonary embolism
• Stroke: Increased risk, particularly in women ≥65 years
• Cardiovascular Disease: Not indicated for prevention of cardiovascular disease
• Contraindicated in Pregnancy: Pregnancy category X
• Not for Premenopausal Women: Only indicated for postmenopausal women
• Black Box Warning Update (November 2025): The FDA initiated removal of these warnings, recognizing that risks and benefits depend heavily on age and timing of initiation, with benefits often outweighing risks for appropriate candidates

Bioavailability and Pharmacokinetics:

Bazedoxifene has an oral bioavailability of around 6%, with a terminal elimination half-life of approximately 27-30 hours. Administration with a high-fat/high-calorie meal caused no change in bazedoxifene's Cmax, but it increased the AUC by 25%.

Advantages Over Other SERMs:

1. Superior Endometrial Safety: Unlike tamoxifen, does not increase endometrial cancer risk
2. No Vasomotor Symptom Worsening: Unlike raloxifene, does not worsen hot flashes when combined with estrogen
3. Unique Combination Therapy: Only SERM approved for combination with estrogen without requiring progestin
4. Bone Protection: Effective for osteoporosis prevention with 35-42% vertebral fracture risk reduction

Limitations:

1. Not Available as Monotherapy in US: Only available combined with conjugated estrogens
2. No Generic Available: Brand-name only, higher cost than generic SERMs
3. VTE Risk: Like all SERMs, carries thromboembolic risk
4. Limited to Postmenopausal Women: Not approved for premenopausal use

Goal Relevance:

• I want to reduce hot flashes and night sweats during menopause.
• I'm looking to prevent bone loss and strengthen my bones after menopause.
• I need a treatment for menopausal symptoms that doesn't increase my risk of uterine cancer.
• I'm searching for a hormone therapy that helps with menopausal symptoms without the need for additional progestin.
• I want to manage my menopausal symptoms while minimizing the risk of blood clots and stroke.

2. Mechanism of Action

2.1 Selective Estrogen Receptor Modulator (SERM) Concept

Selective estrogen receptor modulators (SERMs) are a class of compounds that interact with estrogen receptors (ERs) and exert tissue-selective agonist or antagonist effects. Unlike pure estrogen agonists (like estradiol) or pure antagonists, SERMs have mixed activity that varies by tissue.

Estrogen Receptor Subtypes:

• ERα (Estrogen Receptor Alpha): Predominantly expressed in uterus, breast, bone, brain
• ERβ (Estrogen Receptor Beta): Predominantly expressed in ovaries, prostate, cardiovascular system, CNS

The tissue-selective effects of SERMs arise from:

1. Differential expression of ERα and ERβ in various tissues
2. Tissue-specific coregulator proteins (coactivators and corepressors)
3. Different conformational changes induced in the ER by different ligands

2.2 Bazedoxifene as a Third-Generation SERM

Generational Evolution of SERMs:

• First Generation: Tamoxifen (1977) - breast antagonist, uterine agonist
• Second Generation: Raloxifene (1997) - breast/uterine antagonist, bone agonist
• Third Generation: Bazedoxifene (2013) - improved endometrial safety, no vasomotor worsening

Bazedoxifene is a third-generation selective estrogen receptor modulator (SERM) that has been approved for the prevention and treatment of postmenopausal osteoporosis.

Bazedoxifene is a novel, non-steroidal, indole-based SERM developed using raloxifene as a template with the benzothiophene core substituted by an indole ring.

2.3 Receptor Binding and Affinity

Estrogen Receptor Binding:

Bazedoxifene binds to both ERα (IC50 23 ± 15 nM) and ERβ (IC50 89 ± 159 nM) with high affinity.

Comparison to Raloxifene:

Bazedoxifene binds to both ERα and ERβ, with a slightly higher affinity for ERα; however, it is less ERα-selective than raloxifene, with an affinity for ERα that is approximately 10-fold lower than 17β-estradiol.

Unique Conformational Changes:

Bazedoxifene, lasofoxifene, and raloxifene facilitate conformational changes in ERα that are distinct from those observed in the presence of 4-hydroxytamoxifen.

This unique conformational change explains bazedoxifene's distinct pharmacological profile compared to earlier SERMs.

2.4 Tissue-Selective Effects

Bone (Agonist Effect):

In bone tissue, bazedoxifene acts as an estrogen agonist:

• Decreases bone resorption and reduces biochemical markers of bone turnover to the premenopausal range
• Increases bone mineral density (BMD) at the spine and hip
• Reduces vertebral fracture risk by 35-42%
• Mechanism: Inhibits osteoclast activity and promotes osteoblast function

Uterus/Endometrium (Antagonist Effect):

In endometrial tissue, bazedoxifene acts as an estrogen antagonist:

• Exhibits estrogen antagonistic effects on the endometrium when given alone and concomitantly with conjugated estrogens
• No substantial effect on endometrial thickness or endometrial hyperplasia
• At 12 months, endometrial hyperplasia incidence was low (<1%) and similar among treatment groups
• This is the KEY advantage over tamoxifen, which stimulates endometrial growth

Breast (Antagonist Effect):

In breast tissue, bazedoxifene acts as an estrogen antagonist:

• In breast cancer or uterine carcinoma/endometrial hyperplasia, bazedoxifene acts as a competitive antagonist, yielding antiproliferative effects
• A recent 2025 multidatabase cohort study found that conjugated estrogens/bazedoxifene (CE/BZA) users had breast cancer incidence was lower compared to EP users, with 9.1 fewer cases per 10,000 person-years
• Inhibits estrogen receptor signaling in breast epithelium
• Bazedoxifene had a unique mechanism of action and inhibited the growth of both tamoxifen sensitive and resistant ERα positive breast cancer xenografts

Cardiovascular System (Agonist Effect):

In cardiovascular tissues, bazedoxifene has beneficial estrogen-like effects:

• The advantage of bazedoxifene over raloxifene is that it increases endothelial nitric oxide synthase activity
• Improves lipid profile (reduces LDL cholesterol, increases HDL cholesterol)
• May have favorable effects on vascular function

Central Nervous System (Neutral/Weak Antagonist Effect):

Unlike raloxifene, bazedoxifene has minimal CNS antagonist effects:

• The lack of vasomotor effects compared with raloxifene is a unique advantage
• Does not antagonize the effect of 17β-estradiol on vasomotor symptoms
• This allows combination with estrogen for hot flash treatment (unlike raloxifene which worsens hot flashes)

Comparison to Raloxifene:

Bazedoxifene is a more selective SERM than raloxifene, having a greater ER antagonist effect on the endometrium and lower antagonist effect in the CNS.

2.5 Molecular Signaling Pathways

Anti-Proliferative Effects:

The biomolecular antagonistic effects arise from a pro-apoptotic signal, enabling bazedoxifene to inhibit STAT3 and MAPK signaling pathways and effectively eliminate cancer cells.

Mechanism in Breast Cancer Cells:

Research demonstrates that bazedoxifene:

• Down-regulates estrogen receptor alpha (ERα) expression
• Down-regulates cyclin D1 (cell cycle regulator)
• Inhibits hormone-independent breast cancer cell growth
• May have utility in treating endocrine-resistant breast cancer

2.6 Unique "Tissue Selective Estrogen Complex" (TSEC) Concept

When bazedoxifene is combined with conjugated estrogens (as in Duavee), the combination represents a novel approach called a "Tissue Selective Estrogen Complex" (TSEC):

TSEC Mechanism:

• Conjugated estrogens: Provide estrogen agonist effects where beneficial (bone, vasomotor symptoms, vaginal atrophy)
• Bazedoxifene: Blocks estrogen effects where harmful (endometrium, breast)
• Result: Benefits of estrogen WITHOUT the need for progestin to protect the endometrium

Why This is Unique:

Traditional hormone therapy for women with an intact uterus requires:

• Estrogen + Progestin (to protect endometrium from estrogen-induced hyperplasia)

TSEC approach (bazedoxifene/conjugated estrogens):

• Estrogen + Bazedoxifene (SERM provides endometrial protection)
• No progestin needed
• Avoids progestin-related side effects (bloating, mood changes, potential breast cancer risk)

2.7 Effects on Bone Remodeling

Mechanism of Bone Protection:

Bazedoxifene's bone-protective effects involve:

1. Inhibition of Osteoclasts (Bone Resorption):

   • Binds to ERα on osteoclasts
   • Promotes osteoclast apoptosis
   • Reduces RANKL (receptor activator of nuclear factor kappa-B ligand) signaling
   • Decreases bone resorption markers (CTX, NTX)

2. Promotion of Osteoblasts (Bone Formation):

   • Binds to ERα on osteoblasts
   • Supports osteoblast survival and function
   • Maintains bone formation markers

3. Net Effect:

   • Shifts balance toward bone formation
   • Increases bone mineral density
   • Reduces fracture risk

Biochemical Markers:

Bazedoxifene treatment leads to:

• Decreased serum CTX (C-terminal telopeptide of type I collagen) - marker of bone resorption
• Decreased serum NTX (N-terminal telopeptide of type I collagen) - marker of bone resorption
• Maintained or slightly increased bone-specific alkaline phosphatase - marker of bone formation

2.8 Comparison to Other SERMs by Mechanism

2.9 Clinical Implications of the Mechanism

1. Endometrial Protection Without Progestin:

Because bazedoxifene strongly antagonizes endometrial ER, it can be combined with estrogen WITHOUT requiring progestin. This is the basis for Duavee's approval.

2. Vasomotor Symptom Treatment:

Unlike raloxifene, bazedoxifene does not worsen hot flashes. Combined with estrogen, it effectively treats vasomotor symptoms while protecting the endometrium.

3. Bone Protection:

The ER agonist effect in bone makes bazedoxifene effective for osteoporosis prevention, with 35-42% vertebral fracture risk reduction.

4. Breast Cancer Prevention Potential:

The breast ER antagonist effect, combined with ability to inhibit tamoxifen-resistant breast cancer growth, suggests potential utility beyond osteoporosis (though not yet FDA-approved for breast cancer prevention).

5. Cardiovascular Benefits:

Increased endothelial nitric oxide synthase activity may provide cardiovascular benefits beyond lipid improvement.

3. Indications and Usage

3.1 FDA-Approved Indications (Duavee Combination Only)

Bazedoxifene is FDA-approved ONLY as part of the combination product Duavee (bazedoxifene 20 mg + conjugated estrogens 0.45 mg). Bazedoxifene monotherapy is NOT FDA-approved in the United States.

DUAVEE is indicated for:

1. Treatment of Moderate-to-Severe Vasomotor Symptoms Associated with Menopause:

DUAVEE is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause in postmenopausal women with an intact uterus.

2. Prevention of Postmenopausal Osteoporosis:

DUAVEE is indicated for the prevention of postmenopausal osteoporosis in women with an intact uterus.

Important Limitation: Duavee is indicated for PREVENTION, not treatment, of osteoporosis. For women with established osteoporosis (prior fracture or very low bone density), bisphosphonates or other bone-specific therapies are preferred.

3.2 Patient Selection Criteria

Essential Criteria for Duavee Use:

1. Postmenopausal Status:

Duavee is only appropriate for postmenopausal women, defined as:

• Age ≥60 years (presumed postmenopausal)
• Age <60 with bilateral oophorectomy (surgical menopause)
• Age <60 with spontaneous amenorrhea ≥12 months AND:
  • FSH and estradiol levels in postmenopausal range

2. Intact Uterus:

Duavee is specifically designed for women with an intact uterus. The bazedoxifene component provides endometrial protection from the estrogen component.

Women who have had a hysterectomy:

• Do NOT need Duavee (no endometrial protection needed)
• Should use estrogen-alone therapy (e.g., Premarin, estradiol)

3. Vasomotor Symptoms (for Hot Flash Indication):

For the vasomotor symptom indication:

• Moderate-to-severe hot flashes
• Frequency and severity interfering with quality of life
• Non-hormonal treatments inadequate or not tolerated

4. Osteoporosis Risk (for Prevention Indication):

For the osteoporosis prevention indication:

• Increased risk of osteoporosis based on:
  • Low baseline bone mineral density (T-score -1.0 to -2.5, osteopenia)
  • Risk factors: age, family history, low body weight, smoking, alcohol use, corticosteroid use

5. No Contraindications:

Patients must not have:

• Active or history of venous thromboembolism (DVT, PE)
• Active or history of arterial thromboembolic disease (stroke, MI)
• Known or suspected estrogen-dependent neoplasm (breast cancer, endometrial cancer)
• Abnormal undiagnosed vaginal bleeding
• Liver dysfunction or disease
• Known hypersensitivity
• Pregnancy or may become pregnant

3.3 Clinical Use Scenarios

Scenario 1: Postmenopausal Woman with Hot Flashes and Intact Uterus

Patient Profile:

• 52-year-old woman, 2 years postmenopausal
• Severe hot flashes (10-15 per day), night sweats
• Intact uterus
• No contraindications to estrogen

Treatment Options:

1. Estrogen + progestin (e.g., Prempro, Climara Pro)
2. Duavee (estrogen + bazedoxifene)

Why Choose Duavee:

• Avoids progestin-related side effects (bloating, mood changes)
• Simpler regimen (one pill daily vs. combination)
• Provides endometrial protection without progestin

Scenario 2: Postmenopausal Woman at Risk for Osteoporosis with Vasomotor Symptoms

Patient Profile:

• 55-year-old woman, 5 years postmenopausal
• Moderate hot flashes
• DEXA scan: T-score -1.8 (osteopenia) at lumbar spine
• Intact uterus
• Family history of osteoporosis

Treatment with Duavee:

• Addresses BOTH vasomotor symptoms AND osteoporosis prevention
• Single medication for dual indication
• More convenient than separate therapies

Scenario 3: Woman Who Cannot Tolerate Progestins

Patient Profile:

• 53-year-old woman
• Severe hot flashes
• Tried estrogen + progestin (Prempro) but experienced:
  • Bloating
  • Mood changes
  • Breast tenderness
• Intact uterus

Switch to Duavee:

• Eliminates progestin-related side effects
• Maintains vasomotor symptom relief
• Provides endometrial protection without progestin

3.4 International Approval of Bazedoxifene Monotherapy

Outside the United States:

Bazedoxifene as monotherapy (brand name Viviant) is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy.

Indications for Monotherapy (EU/Japan):

• Treatment of postmenopausal osteoporosis
• Reduction of vertebral fracture risk
• Dose: 20 mg once daily

Why Not Approved in US as Monotherapy:

The FDA approved bazedoxifene only in combination with conjugated estrogens (Duavee) based on the specific clinical trial data submitted for that combination. Bazedoxifene monotherapy was not pursued for FDA approval in the US, possibly due to:

• Commercial strategy to differentiate as a unique TSEC product
• Competition from generic raloxifene for osteoporosis prevention
• Preference for combination therapy addressing multiple menopausal symptoms

3.5 Off-Label Uses (Not FDA-Approved)

1. Treatment (Not Just Prevention) of Osteoporosis:

While Duavee is approved only for osteoporosis PREVENTION, it may be used off-label for treatment of established osteoporosis:

• Based on fracture reduction data from monotherapy trials
• Less robust evidence than bisphosphonates or denosumab
• Consider for women who also need vasomotor symptom treatment

2. Breast Cancer Prevention:

Bazedoxifene has shown promise in research:

• Bazedoxifene had a unique mechanism of action and inhibited the growth of both tamoxifen sensitive and resistant ERα positive breast cancer xenografts
• NOT FDA-approved for breast cancer prevention
• Raloxifene IS FDA-approved for breast cancer risk reduction
• May be considered in women at high breast cancer risk who also need vasomotor symptom treatment

3. Treatment of Tamoxifen-Resistant Breast Cancer:

Preclinical research suggests potential:

• Inhibits growth of tamoxifen-resistant ER+ breast cancer in animal models
• NOT FDA-approved
• Clinical trials would be needed

3.6 Inappropriate Uses

Duavee is NOT Appropriate for:

1. Women Who Have Had a Hysterectomy:

• No endometrial protection needed
• Should use estrogen-alone therapy
• Bazedoxifene component unnecessary

2. Premenopausal Women:

• Only indicated for postmenopausal women
• Safety and efficacy not established in premenopausal women

3. Men:

• Not approved for use in men
• No safety or efficacy data

4. Treatment of Established Osteoporosis as First-Line:

• FDA-approved only for PREVENTION
• Bisphosphonates or denosumab preferred for treatment

5. Prevention of Cardiovascular Disease:

• NOT indicated for cardiovascular disease prevention
• May increase stroke risk in some populations

3.7 When to Choose Duavee Over Other Hormone Therapies

Choose Duavee When:

1. Woman with Intact Uterus Needs Vasomotor Symptom Treatment:

• Alternative to estrogen + progestin
• Avoids progestin side effects

2. Woman Cannot Tolerate Progestins:

• Bloating, mood changes, breast tenderness from progestins
• Duavee provides endometrial protection without progestin

3. Dual Need: Vasomotor Symptoms + Osteoporosis Prevention:

• Single medication addresses both
• More convenient than multiple therapies

4. Preference for Novel TSEC Approach:

• Patient preference for innovative therapy
• Concerns about progestin and breast cancer risk

Choose Other Therapies When:

1. Post-Hysterectomy:

• Use estrogen alone (no endometrial protection needed)
• Duavee unnecessary and more expensive

2. Osteoporosis Treatment (Not Just Prevention):

• Bisphosphonates or denosumab preferred
• Stronger fracture reduction evidence

3. Cost Concerns:

• Generic estrogen + progestin much cheaper
• Duavee is brand-name only (~$99-248/month)

4. History of VTE or Stroke:

• Increased risk with all estrogen-containing therapies
• Consider non-hormonal alternatives

4. Dosing and Administration

4.1 Standard Dosing for Duavee

Standard Dose:

The recommended dose is one tablet once daily.

Duavee Tablet Composition:

• Bazedoxifene 20 mg + Conjugated Estrogens 0.45 mg per tablet

Important Note: There is no 40 mg bazedoxifene formulation of Duavee. All current sources from 2025 only reference the single available strength of 20 mg bazedoxifene combined with 0.45 mg conjugated estrogens.

Key Dosing Points:

• Dose: One tablet (20 mg bazedoxifene/0.45 mg CE) once daily
• Timing: Can be taken at any time of day
• Food: May be taken with or without food (though food increases bazedoxifene AUC by 25%, no dose adjustment needed)
• Consistency: Take at approximately the same time each day
• Missed Dose: Take as soon as remembered; if close to next dose, skip and resume regular schedule (do not double dose)

4.2 Initiating Therapy

Before Starting Duavee:

1. Confirm Postmenopausal Status:

   • For women <60 years, confirm with FSH and estradiol levels
   • Ensure spontaneous amenorrhea ≥12 months

2. Baseline Assessments:

   • Complete medical history and physical examination
   • Breast examination and mammography
   • Pelvic examination with Pap smear
   • Endometrial assessment if abnormal vaginal bleeding
   • DEXA scan if considering for osteoporosis prevention
   • Lipid panel
   • Liver function tests

3. Evaluate Contraindications:

   • History of VTE, stroke, MI
   • Breast cancer or other estrogen-dependent neoplasm
   • Liver dysfunction
   • Abnormal vaginal bleeding

Starting Dose:

Always start with one tablet daily. There is no titration or dose adjustment based on response.

4.3 Duration of Treatment

General Principle:

Use the lowest effective dose for the shortest duration consistent with treatment goals and risks for the individual woman.

For Vasomotor Symptoms:

• Initial trial: 3-6 months to assess efficacy
• Reassess periodically: Every 6-12 months
• Duration: As long as benefits outweigh risks
• Consider discontinuation attempt: Every 1-2 years to see if symptoms have resolved

For Osteoporosis Prevention:

• Long-term therapy: May be used for years if benefits outweigh risks
• Reassess periodically: Annual risk-benefit assessment
• DEXA monitoring: Every 2 years to assess bone density changes

Current Recommendations (2025):

Following the FDA's November 2025 removal of blanket warnings, duration decisions should be individualized based on:

• Age at initiation (younger women generally safer)
• Time since menopause
• Osteoporosis risk
• Cardiovascular risk factors
• VTE risk factors
• Patient preference

4.4 Dose Adjustments

Renal Impairment:

No dose adjustment specified in FDA labeling. Bazedoxifene is primarily eliminated in feces, with minimal renal excretion.

Hepatic Impairment:

Patients with hepatic impairment are strongly advised against using this drug. Duavee is contraindicated in women with hepatic impairment or liver disease.

Elderly Patients (≥65 Years):

No dose adjustment based on age alone. However:

• Increased risk of stroke in women ≥65 years
• Increased risk of dementia in women ≥65 years
• Risk-benefit assessment critical in this age group

Race/Ethnicity:

No dose adjustment based on race or ethnicity.

Body Weight:

No dose adjustment based on body weight or BMI.

4.5 Switching from Other Hormone Therapies

Switching from Estrogen + Progestin (e.g., Prempro):

When Switching:

• Woman with intact uterus on estrogen + progestin
• Experiencing progestin-related side effects (bloating, mood changes)
• Desires to avoid progestin

How to Switch:

• Stop estrogen + progestin
• Start Duavee the next day
• No washout period required

Switching from Estrogen Alone (Woman with Intact Uterus - Inappropriate Therapy):

If a woman with an intact uterus is taking estrogen alone (INAPPROPRIATE - no endometrial protection):

• Stop estrogen alone immediately
• Start Duavee the next day
• Schedule endometrial assessment if on estrogen alone >3-6 months

Switching from Raloxifene (for Osteoporosis Prevention):

When Switching:

• Woman on raloxifene for osteoporosis prevention
• Develops moderate-to-severe vasomotor symptoms
• Desires vasomotor symptom relief in addition to bone protection

How to Switch:

• Stop raloxifene
• Start Duavee the next day
• Note: Raloxifene WORSENS hot flashes; Duavee (estrogen component) IMPROVES hot flashes

Switching from Duavee to Other Therapies:

To Estrogen Alone (After Hysterectomy):

• If woman has hysterectomy after starting Duavee
• Stop Duavee
• Switch to estrogen alone (bazedoxifene no longer needed for endometrial protection)

To Bisphosphonate (for Osteoporosis Treatment):

• If woman develops osteoporosis (fracture or T-score ≤-2.5)
• May discontinue Duavee and start bisphosphonate
• OR continue Duavee for vasomotor symptoms and add bisphosphonate

4.6 Administration Instructions

Tablet Administration:

• The tablets are oval, biconvex, pink tablets, branded with "0.45/20" in black ink on one side
• Swallow tablets whole with water
• Do not crush, break, or chew tablets
• May be taken with or without food

Food Effects:

Administration with a high-fat/high-calorie meal caused no change in bazedoxifene's Cmax, but it increased the AUC by 25%.

However, no dose adjustment is recommended based on food intake. Patients may take Duavee with or without food based on preference.

Storage Considerations:

Store each tablet in its blister pack until you are ready to take it. Do not use a pill box for this medicine.

Write down the date you open a Duavee foil pouch. Use the medicine within 60 days after opening the pouch.

4.7 Concomitant Medications to Avoid

Do NOT Take with Duavee:

Women taking Duavee should not take progestins, additional estrogens or additional estrogen agonist/antagonists.

Specifically Avoid:

• Progestins (progesterone, medroxyprogesterone, norethindrone, etc.)
• Additional estrogens (estradiol, estrone, other conjugated estrogen products)
• Other SERMs (raloxifene, tamoxifen)

Rationale:

• Duavee already contains estrogen (conjugated estrogens 0.45 mg)
• Duavee already provides endometrial protection (bazedoxifene)
• Adding additional hormones is unnecessary and increases risk

4.8 Adherence Strategies

Long-term adherence to hormone therapy is challenging. Strategies to improve adherence:

1. Link to Daily Routine:

• Take at the same time each day
• Associate with a daily activity (e.g., after breakfast, before bed)

2. Medication Reminders:

• Phone alarms
• Medication reminder apps
• Calendar notifications

3. Blister Pack Tracking:

• Blister pack design helps track doses
• Easy to see if dose was missed

4. Side Effect Management:

• Address side effects promptly
• Adjust timing (if nausea, take at bedtime)
• Reassure about transient side effects (often improve over time)

5. Patient Education:

• Explain benefits for both vasomotor symptoms and bone health
• Discuss realistic expectations
• Address concerns about risks

6. Regular Follow-Up:

• Schedule 3-6 month follow-up after starting
• Annual visits thereafter
• Provides opportunity to address concerns

4.9 Discontinuation

When to Consider Discontinuing Duavee:

1. Vasomotor Symptoms Resolved:

• Trial discontinuation every 1-2 years
• If symptoms recur, can restart

2. Adverse Events:

• VTE, stroke, or other serious adverse event
• Intolerable side effects

3. Development of Contraindication:

• Breast cancer diagnosis
• Abnormal vaginal bleeding (requires evaluation)
• Liver disease

4. Patient Preference:

• Desire to stop hormone therapy
• Concerns about risks

How to Discontinue:

Abrupt Discontinuation:

• Can stop immediately (no taper required)
• Vasomotor symptoms may recur within days to weeks

Gradual Taper (Optional):

• Some clinicians recommend gradual taper
• No evidence that taper reduces symptom recurrence
• May try every-other-day dosing for 1-2 weeks before stopping

After Discontinuation:

• Vasomotor symptoms may recur
• Bone density may decline
• Consider alternative therapies if needed (non-hormonal for hot flashes, bisphosphonates for bone)

5. Pharmacokinetics

5.1 Absorption

Oral Bioavailability:

Bazedoxifene has an oral bioavailability of around 6%, reflecting significant first-pass hepatic metabolism.

The low bioavailability is due to:

• Extensive first-pass metabolism in the gut wall
• Hepatic metabolism before reaching systemic circulation
• Limited absorption from the GI tract

Time to Peak Concentration (Tmax):

The Tmax (time to peak concentration) is 2.5 ± 2.1 hours.

Dose Proportionality:

Bazedoxifene exhibits a linear increase in plasma concentrations for single doses from 0.5 mg up to 120 mg.

This linear pharmacokinetics simplifies dosing and allows predictable drug exposure across the dose range.

Food Effects:

Administration with a high-fat/high-calorie meal caused no change in bazedoxifene's Cmax, but it increased the AUC by 25%.

Clinical Implication:

• Food does not affect peak concentration (Cmax)
• Food increases total exposure (AUC) by 25%
• No dose adjustment recommended based on food
• Patients may take Duavee with or without food

This is in contrast to exemestane (another drug in this class), which REQUIRES food administration for adequate absorption.

5.2 Distribution

Volume of Distribution:

The volume of distribution for bazedoxifene is 14.7 L/kg.

This relatively large volume of distribution indicates extensive tissue distribution.

Protein Binding:

Bazedoxifene is highly bound (98% to 99%) to plasma protein, but not sex hormone-binding globulin.

Clinical Implications:

• High protein binding may lead to drug-drug interactions with other highly protein-bound drugs
• Not bound to SHBG (unlike estradiol), so SHBG changes don't affect bazedoxifene levels
• Only 1-2% is free (active) drug in plasma

Tissue Distribution:

Bazedoxifene distributes widely to:

• Bone (therapeutic target for osteoporosis)
• Uterus/endometrium (antagonist effect)
• Breast (antagonist effect)
• Liver (site of metabolism)
• Other tissues expressing estrogen receptors

5.3 Metabolism

Primary Metabolic Pathway:

Bazedoxifene undergoes extensive metabolism primarily through glucuronidation by UDP-glucuronosyltransferase (UGT), notably in the intestinal wall (UGT1A8 and UGT1A10).

Key Points:

• NOT metabolized by CYP450 enzymes (including CYP3A4)
• Metabolized by UGT enzymes (glucuronidation)
• First-pass metabolism occurs in gut wall (UGT1A8, UGT1A10)
• Hepatic metabolism via UGT enzymes

Major Metabolite:

The major circulating metabolite is bazedoxifene-5-glucuronide, with concentrations in plasma approximately 10-fold higher than that of the unchanged drug.

Metabolite Activity:

Bazedoxifene-5-glucuronide is pharmacologically INACTIVE. The parent drug (bazedoxifene) is responsible for therapeutic effects.

Clinical Significance:

Because bazedoxifene is metabolized by UGT (not CYP450):

• Fewer drug-drug interactions compared to CYP-metabolized drugs
• UGT inducers (rifampin, phenobarbital, carbamazepine, phenytoin) may reduce bazedoxifene levels
• UGT inhibitors have minimal clinical effect

5.4 Elimination

Half-Life:

Bazedoxifene has an elimination half-life of around 30 hours. A more recent study reported a terminal elimination half-life of approximately 27 hours.

Steady-State:

With a 27-30 hour half-life and once-daily dosing:

• Steady-state achieved in approximately 5-7 days (5 half-lives)
• Minimal accumulation with daily dosing

Routes of Excretion:

The primary elimination pathway for bazedoxifene is biliary excretion, with approximately 85% of the dose excreted in feces and less than 1% in urine.

Excretion Summary:

• Feces: 85% (primarily as glucuronide metabolites via bile)
• Urine: <1% (minimal renal excretion)
• Biliary excretion is the predominant elimination route

Enterohepatic Recirculation:

Bazedoxifene undergoes entero-hepatic recycling from the gut back to the systemic circulation.

Mechanism:

1. Bazedoxifene-glucuronide excreted in bile into intestine
2. Intestinal bacteria hydrolyze glucuronide
3. Free bazedoxifene reabsorbed
4. Returns to systemic circulation

This enterohepatic recirculation:

• Prolongs drug residence in the body
• Contributes to the relatively long half-life
• Maintains more stable drug levels

5.5 Special Populations

Renal Impairment:

No specific pharmacokinetic studies in renal impairment, but:

• Bazedoxifene is primarily eliminated via feces (<1% in urine)
• Renal impairment unlikely to significantly affect bazedoxifene pharmacokinetics
• No dose adjustment required for renal impairment

Hepatic Impairment:

A 2018 study evaluated pharmacokinetics and safety of bazedoxifene in hepatically impaired and healthy postmenopausal women.

Key Findings:

• Drug exposure increased in hepatic impairment
• Safety concerns in hepatically impaired patients

Patients with hepatic impairment are strongly advised against using this drug as it may result in unintended pharmacological effects due to ineffective metabolism and inadequate drug clearance.

Contraindication:

Duavee is CONTRAINDICATED in women with hepatic impairment or liver disease.

Elderly Patients (≥65 Years):

No significant pharmacokinetic differences based on age alone.

However, elderly women (≥65 years) have increased risks of:

• Stroke
• Dementia
• These are pharmacodynamic (clinical effect) risks, not pharmacokinetic differences

Race/Ethnicity:

Limited data suggest no clinically significant pharmacokinetic differences based on race or ethnicity.

Body Weight/BMI:

No dose adjustment required based on body weight or BMI.

5.6 Drug-Drug Interaction Pharmacokinetics

CYP3A4 Effects (on Conjugated Estrogens Component):

While bazedoxifene is NOT metabolized by CYP450 enzymes, the conjugated estrogens component of Duavee IS partially metabolized by CYP3A4.

Estrogens undergo partial metabolism by cytochrome CYP3A4. This creates potential for drug-drug interactions.

CYP3A4 Inhibitors (Affect Estrogen, Not Bazedoxifene):

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone.

Strong CYP3A4 Inhibitors:

• Itraconazole, ketoconazole (antifungals)
• Ritonavir, indinavir (HIV protease inhibitors)
• Clarithromycin, erythromycin (macrolide antibiotics)

CYP3A4 inhibitors may increase levels of conjugated estrogens and the risk of endometrial hyperplasia.

Clinical Significance:

• Modest increases in drug exposure
• Monitor for increased estrogenic effects (breast tenderness, nausea)
• Consider alternative therapy or close monitoring

CYP3A4 Inducers (Affect Estrogen, Not Bazedoxifene):

Inducers of CYP3A4, such as phenobarbital, carbamazepine, St John's wort, and rifampin, can decrease estrogen concentrations, leading to reduced efficacy and alterations in the uterine bleeding profile.

Clinical Significance:

• Reduced estrogen levels
• May reduce efficacy for vasomotor symptoms
• May increase breakthrough bleeding
• Consider alternative therapy or higher estrogen dose (not available with Duavee fixed combination)

UGT Inducers (Affect Bazedoxifene, Not Estrogen):

Bazedoxifene does not induce or inhibit the activities of major CYP isoenzymes, and in vitro data suggest that bazedoxifene is unlikely to interact with co-administered drugs via CYP-mediated metabolism. However, the metabolism of bazedoxifene may be increased by concomitant use of substances known to induce UGTs, such as rifampin, phenobarbital, carbamazepine, and phenytoin.

Clinical Significance:

A reduction in bazedoxifene exposure may be associated with an increased risk of endometrial hyperplasia.

UGT Inducers:

• Rifampin
• Phenobarbital
• Carbamazepine
• Phenytoin

Management:

• Avoid concomitant use if possible
• Consider alternative hormone therapy
• Monitor for endometrial safety (ultrasound, biopsy if abnormal bleeding)

5.7 Pharmacokinetic Summary Table

5.8 Clinical Implications of Pharmacokinetics

1. Once-Daily Dosing:

The 27-30 hour half-life supports convenient once-daily dosing with stable drug levels.

2. Minimal Renal Considerations:

<1% renal excretion means:

• Safe in renal impairment
• No dose adjustment for CKD or dialysis

3. Hepatic Contraindication:

Extensive hepatic metabolism means:

• Increased exposure in liver disease
• Contraindicated in hepatic impairment

4. Food Flexibility:

Unlike some medications, Duavee can be taken with or without food based on patient preference.

5. Drug Interaction Profile:

• Fewer CYP-mediated interactions (bazedoxifene not CYP substrate)
• UGT inducers require caution
• CYP3A4 inducers/inhibitors affect estrogen component

6. Steady-State Predictability:

Linear pharmacokinetics and once-daily dosing lead to predictable steady-state within 5-7 days.

6. Side Effects and Adverse Reactions

6.1 Overview

The safety of conjugated estrogens/bazedoxifene was evaluated in four Phase 3 clinical trials ranging from 12 weeks to 24 months in duration and enrolling 6,210 postmenopausal women age 40 to 75 years (mean age 55 years), with 1,224 patients treated with DUAVEE and 1,069 patients receiving placebo.

The incidence of serious adverse reactions was 3.5% in the DUAVEE group and 4.8% in the placebo group.

6.2 Most Common Adverse Effects (≥5% Incidence)

The most common adverse reactions occurring in ≥5% of patients are muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain.

1. Muscle Spasms:

• Incidence: ≥5%
• Typically involve legs (calf cramps)
• Often nocturnal
• May improve with calcium/magnesium supplementation

2. Nausea:

• Incidence: ≥5%
• Usually mild and transient
• Often improves within first few weeks
• Taking with food may help
• Taking at bedtime may reduce daytime nausea

3. Diarrhea:

• Incidence: ≥5%
• Usually mild
• Transient in most cases

4. Dyspepsia (Indigestion):

• Incidence: ≥5%
• Upper abdominal discomfort
• May be related to estrogen component

5. Upper Abdominal Pain:

• Incidence: ≥5%
• Usually mild
• If severe or persistent, evaluate for other causes

6. Oropharyngeal Pain (Sore Throat):

• Incidence: ≥5%
• Not specific to Duavee
• May be coincidental

7. Dizziness:

• Incidence: ≥5%
• Usually mild
• Advise caution with driving/operating machinery initially

8. Neck Pain:

• Incidence: ≥5%
• Not clearly related to mechanism of action
• May be coincidental

6.3 Serious Adverse Effects

Venous Thromboembolism (VTE):

Venous thromboembolic events, primarily deep vein thromboses, were more frequently reported in the active treatment groups compared with the placebo group.

The overall incidence of venous thromboembolism in the active bazedoxifene treatment groups was very low in both phase III trials (below 1%), but was significantly higher than placebo in one study.

Incidence:

• Deep vein thrombosis: <1% but higher than placebo
• Pulmonary embolism: Rare

Risk Factors for VTE:

• History of VTE
• Prolonged immobilization (surgery, long flights)
• Obesity
• Smoking
• Thrombophilia (Factor V Leiden, etc.)
• Age

Management:

• Screen for VTE history before prescribing
• Discontinue Duavee if VTE occurs
• Discontinue 4-6 weeks before major surgery
• Counsel on VTE symptoms (leg swelling, chest pain, shortness of breath)

Stroke:

Estrogen agonist/antagonists (including bazedoxifene, a component of DUAVEE) and estrogens individually are known to increase the risk of VTE. An increased risk of stroke and DVT has been reported with estrogen-alone therapy.

Risk particularly elevated in:

• Women ≥65 years
• Women with cardiovascular risk factors
• Women with history of stroke or TIA

Management:

• Assess stroke risk before prescribing
• Consider non-hormonal alternatives in high-risk women
• Discontinue if stroke occurs

Cardiovascular Events:

The rates of cardiac disorders and cerebrovascular events were low and evenly distributed among groups.

No significant increase in myocardial infarction or other cardiac events compared to placebo.

Dementia:

Increased risk of probable dementia observed in postmenopausal women ≥65 years of age receiving daily dosages of oral conjugated estrogens alone.

This warning comes from the Women's Health Initiative Memory Study (WHIMS), which studied estrogen-alone therapy.

Recommendation:

• Duavee should not be used for prevention of dementia
• Consider risks vs. benefits carefully in women ≥65 years

6.4 Endometrial and Uterine Effects

Endometrial Hyperplasia:

At 12 months, endometrial hyperplasia incidence was low (<1%) and similar among treatment groups.

There was no difference in the rates of endometrial hyperplasia or carcinoma with bazedoxifene compared with placebo, or in the change in endometrial thickness.

Key Finding:

Unlike estrogen + progestin (which requires progestin to protect endometrium), Duavee's bazedoxifene component provides endometrial protection WITHOUT progestin.

2025 Update:

A recent 2025 multidatabase cohort study found that conjugated estrogens/bazedoxifene (CE/BZA) users had slightly higher rates of endometrial cancer and endometrial hyperplasia compared to estrogen/progestin (EP) users, with 1.6 and 0.4 additional cases per 10,000 person-years, respectively, though precision was limited by small case numbers.

Clinical Implication:

While endometrial hyperplasia incidence remains very low (<1%), real-world data suggest slightly higher rates than estrogen/progestin. Close monitoring remains important.

Abnormal Vaginal Bleeding:

May occur in some women:

• Irregular bleeding or spotting
• Withdrawal bleeding if recently switched from estrogen + progestin
• Any abnormal bleeding requires evaluation to rule out endometrial pathology

6.5 Breast Effects

Breast Cancer:

Breast cancer incidence was lower in CE/BZA users compared to EP users, with 9.1 fewer cases per 10,000 person-years.

This suggests Duavee may have a MORE FAVORABLE breast cancer profile than estrogen + progestin.

Breast Tenderness:

May occur due to estrogen component:

• Usually mild
• Often improves within first few months
• If persistent, may reduce dose (though Duavee only available in one strength)

Fibrocystic Breast Changes:

Estrogen may worsen fibrocystic changes:

• Monitor with annual mammography
• Evaluate any new breast lumps

6.6 Comparison to Bazedoxifene Monotherapy Safety Profile

Monotherapy Trials (Outside US):

The incidence of adverse events, serious adverse events, and discontinuations due to adverse events in the bazedoxifene groups was not different from that seen in the placebo group.

Key Findings from Monotherapy:

• Generally safe and well tolerated, with favorable endometrial and breast safety profiles
• Hot flushes and leg cramps were higher with bazedoxifene or raloxifene compared with placebo

Difference with Duavee:

• Duavee (combination with estrogen) IMPROVES hot flashes
• Bazedoxifene monotherapy WORSENS hot flashes (like raloxifene)
• This is a KEY advantage of the combination product

6.7 Comparison to Other Hormone Therapies

Duavee vs. Estrogen + Progestin:

Key Advantages of Duavee:

• No progestin-related side effects (breast tenderness, bloating, mood)
• Potentially lower breast cancer risk

Key Disadvantages of Duavee:

• More muscle spasms
• Brand-name only (more expensive)

6.8 Management of Common Side Effects

Muscle Spasms:

Management:

• Calcium 1200 mg daily + Magnesium 400-500 mg daily
• Adequate hydration
• Stretching exercises before bed
• Tonic water (quinine) - some patients find helpful
• If severe and persistent, consider switching to estrogen + progestin

Nausea:

Management:

• Take with food
• Take at bedtime
• Ginger supplements
• If persistent beyond 4-6 weeks, reassess

Gastrointestinal Symptoms (Diarrhea, Dyspepsia):

Management:

• Usually transient
• Dietary modifications
• Over-the-counter antacids for dyspepsia
• If persistent, evaluate for other causes

Dizziness:

Management:

• Advise caution with position changes (orthostatic hypotension)
• Take at bedtime if daytime dizziness
• Check blood pressure
• If persistent, evaluate for other causes

6.9 When to Discontinue Duavee

Immediate Discontinuation Required:

1. Venous thromboembolism (DVT, PE)
2. Stroke or TIA
3. Myocardial infarction
4. Retinal vascular thrombosis (sudden vision loss)
5. Liver disease or jaundice
6. Pregnancy
7. Breast cancer diagnosis
8. Abnormal vaginal bleeding (discontinue pending evaluation)

Consider Discontinuation:

1. Intolerable side effects not responding to management
2. Development of contraindication
3. Patient preference

6.10 Black Box Warnings (Updated November 2025)

Historical Black Box Warnings (Pre-2025):

Like all estrogen-containing products, Duavee historically carried black box warnings for:

• Cardiovascular disorders (stroke, VTE)
• Breast cancer
• Endometrial cancer (estrogen-alone in women with intact uterus)
• Dementia

November 2025 FDA Update:

In November 2025, the FDA initiated removal of these warnings, recognizing that risks and benefits depend heavily on age and timing of initiation, with benefits often outweighing risks for appropriate candidates, while noting that doctor-patient consultation remains crucial.

Current Approach (Post-November 2025):

Individualized risk-benefit assessment based on:

• Age at initiation: Younger women (50-59) have more favorable risk-benefit
• Time since menopause: Early menopause (within 10 years) more favorable
• Duration of use: Short-term use (<5 years) lower risk
• Risk factors: Cardiovascular, VTE, breast cancer family history
• Symptom severity: Severe symptoms justify higher risk tolerance

7. Drug Interactions

7.1 Overview

Bazedoxifene has relatively few drug interactions because:

• Bazedoxifene does not induce or inhibit the activities of major CYP isoenzymes
• Metabolized by UGT (not CYP450), reducing CYP-mediated interactions

However, the conjugated estrogens component of Duavee IS partially metabolized by CYP3A4, creating potential for interactions.

7.2 CYP3A4 Inhibitors (Affect Estrogen Component)

Strong CYP3A4 Inhibitors:

• Itraconazole, ketoconazole (antifungals)
• Ritonavir, indinavir (HIV protease inhibitors)
• Clarithromycin, erythromycin (macrolide antibiotics)
• Nefazodone (antidepressant)
• Grapefruit juice (in large amounts)

Pharmacokinetic Effect:

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone.

Clinical Significance:

CYP3A4 inhibitors may increase levels of conjugated estrogens and the risk of endometrial hyperplasia.

Management:

• Use caution when co-administering
• Monitor for increased estrogenic effects (nausea, breast tenderness)
• Consider alternative therapy if possible
• Monitor endometrial thickness if long-term use

7.3 CYP3A4 Inducers (Affect Estrogen Component)

Strong CYP3A4 Inducers:

• Rifampin (antibiotic)
• Phenytoin, carbamazepine, phenobarbital (antiepileptics)
• St. John's Wort (herbal supplement)
• Modafinil (wakefulness agent)

Pharmacokinetic Effect:

Inducers of CYP3A4, such as phenobarbital, carbamazepine, St John's wort, and rifampin, can decrease estrogen concentrations, leading to reduced efficacy and alterations in the uterine bleeding profile.

Clinical Significance:

• Reduced estrogen levels
• Decreased efficacy for vasomotor symptoms
• Increased breakthrough bleeding
• Potential loss of endometrial protection

Management:

• Avoid concomitant use if possible
• If unavoidable, consider alternative hormone therapy
• Monitor for breakthrough bleeding
• Monitor for recurrence of hot flashes

7.4 UGT Inducers (Affect Bazedoxifene Component)

UGT Inducers:

• Rifampin
• Phenobarbital
• Carbamazepine
• Phenytoin

Pharmacokinetic Effect:

The metabolism of bazedoxifene may be increased by concomitant use of substances known to induce UGTs, such as rifampin, phenobarbital, carbamazepine, and phenytoin.

Clinical Significance:

A reduction in bazedoxifene exposure may be associated with an increased risk of endometrial hyperplasia.

Mechanism:

• Reduced bazedoxifene levels
• Loss of endometrial protection from estrogen component
• Increased risk of endometrial hyperplasia

Management:

• AVOID concomitant use with UGT inducers
• If unavoidable:
  • Consider alternative hormone therapy (estrogen + progestin)
  • Close endometrial monitoring (ultrasound, biopsy if abnormal bleeding)

Note: Rifampin, phenobarbital, carbamazepine, and phenytoin are BOTH CYP3A4 AND UGT inducers, so they reduce levels of BOTH bazedoxifene and estrogen.

7.5 Drugs That Should NOT Be Co-Administered with Duavee

Absolutely Contraindicated:

1. Progestins:

Women taking Duavee should not take progestins.

Examples:

• Progesterone (Prometrium)
• Medroxyprogesterone acetate (Provera)
• Norethindrone
• Levonorgestrel
• Drospirenone

Rationale:

• Duavee already provides endometrial protection via bazedoxifene
• Adding progestin is unnecessary
• May increase side effects

2. Additional Estrogens:

Women taking Duavee should not take additional estrogens.

Examples:

• Estradiol tablets, patches, gels
• Other conjugated estrogen products (Premarin)
• Vaginal estrogen products (may be acceptable - discuss with provider)

Rationale:

• Duavee already contains 0.45 mg conjugated estrogens
• Additional estrogen increases risk
• May lead to endometrial hyperplasia

3. Additional Estrogen Agonist/Antagonists (SERMs):

Women taking Duavee should not take additional estrogen agonist/antagonists.

Examples:

• Raloxifene (Evista)
• Tamoxifen (Nolvadex)
• Toremifene (Fareston)

Rationale:

• Duavee already contains bazedoxifene (a SERM)
• Combining SERMs may lead to unpredictable effects
• Mechanism of action may interfere with each other

7.6 Thyroid Hormone Interactions

Effect on Thyroid Hormone Levels:

Estrogens increase thyroid-binding globulin (TBG), which can affect thyroid hormone levels:

• Total T4 and T3 increase (due to increased TBG)
• Free T4 and free T3 typically remain normal
• TSH may increase in hypothyroid women on levothyroxine

Clinical Management:

For women on levothyroxine who start Duavee:

• Monitor TSH 6-8 weeks after starting
• May need to increase levothyroxine dose
• Aim for TSH in therapeutic range

7.7 Anticoagulant Interactions

Warfarin:

Estrogens may affect warfarin metabolism and clotting factor synthesis:

• Variable effects on INR
• Close monitoring required

Management:

• Check INR more frequently when starting or stopping Duavee
• Adjust warfarin dose as needed to maintain therapeutic INR

Direct Oral Anticoagulants (DOACs):

No specific interaction data, but:

• Both Duavee and DOACs affect coagulation
• Theoretical increased bleeding risk
• Use caution

7.8 Corticosteroid Interactions

Estrogens may increase cortisol-binding globulin (CBG):

• Total cortisol levels increase
• Free cortisol remains normal
• May affect interpretation of cortisol tests
• No dose adjustment typically needed

7.9 Smoking Interaction

Cigarette Smoking:

Smoking increases the risk of serious cardiovascular events in women taking estrogen-containing products:

• Increased stroke risk
• Increased VTE risk
• Possibly increased cardiovascular risk

Recommendation:

• Advise smoking cessation before starting Duavee
• If unable to quit, carefully weigh risks vs. benefits
• Consider non-hormonal alternatives

7.10 Summary of Clinically Significant Interactions

8. Contraindications

8.1 Absolute Contraindications

1. Pregnancy:

Bazedoxifene/conjugated estrogen is contraindicated for use in pregnant women and is indicated for use only in postmenopausal women.

The FDA has classified the combination of bazedoxifene/conjugated estrogens as pregnancy category X drugs.

Animal Studies:

Animal studies have shown that oral bazedoxifene administered during the period of organogenesis to pregnant rats or rabbits at 0.3 and 2 times, respectively, the exposure at the maximum recommended dose, can cause fetal harm.

Clinical Action:

If pregnancy occurs during treatment, this drug should be withdrawn immediately.

2. Lactation (Breastfeeding):

There are no data on the presence of bazedoxifene in either human or animal breast milk, the effect on the breastfed infant, or the effects on milk production.

Based on its mechanism of action, it is believed that bazedoxifene may inhibit the essential functions of estrogen in mammary tissue during lactation. Estrogens can reduce milk production in breastfeeding mothers.

Contraindication:

Duavee is contraindicated during breastfeeding.

3. Active or History of Venous Thromboembolism (VTE):

Notable contraindications include any previous or current history of DVT, pulmonary embolism.

Included:

• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Retinal vein thrombosis

Rationale:

• Estrogens and SERMs increase VTE risk
• History of VTE indicates high recurrence risk
• Contraindicated even if on anticoagulation

4. Active or History of Arterial Thromboembolic Disease:

Notable contraindications include any previous or current history of stroke, myocardial infarction.

Included:

• Stroke or transient ischemic attack (TIA)
• Myocardial infarction (MI)
• Coronary artery disease with angina

Rationale:

• Estrogens may increase stroke risk
• History indicates high risk

5. Known or Suspected Estrogen-Dependent Neoplasm:

Contraindicated in:

• Breast cancer (current or history)
• Endometrial cancer (current or history)
• Other estrogen-dependent tumors

Rationale:

• Estrogen component may stimulate hormone-sensitive cancers
• Even though bazedoxifene is a SERM with antagonist effects in breast/uterus, estrogen component creates risk

6. Abnormal Undiagnosed Vaginal Bleeding:

Notable contraindications include abnormal uterine bleeding.

Rationale:

• Must rule out endometrial cancer or hyperplasia before starting
• Once diagnosed and treated, may reconsider Duavee

7. Hepatic Impairment or Liver Disease:

Bazedoxifene/conjugated estrogen is contraindicated in patients with hepatic impairment.

Patients with hepatic impairment are strongly advised against using this drug as it may result in unintended pharmacological effects due to ineffective metabolism and inadequate drug clearance.

Included:

• Cirrhosis
• Active hepatitis
• Severe liver dysfunction
• Liver tumors (benign or malignant)

8. Known Hypersensitivity:

Notable contraindications include hypersensitivity or allergic reactions to exogenous estrogen.

Contraindicated in patients with known hypersensitivity to:

• Bazedoxifene
• Conjugated estrogens
• Any component of Duavee

8.2 Relative Contraindications (Use with Extreme Caution)

1. High Risk for VTE or Stroke:

While not absolute contraindications, the following significantly increase risk:

• Obesity (BMI >30)
• Prolonged immobilization
• Thrombophilia (Factor V Leiden, prothrombin mutation, etc.)
• Age ≥65 years (increased stroke risk)
• Uncontrolled hypertension
• Diabetes with vascular complications
• Smoking

Management:

• Carefully weigh risks vs. benefits
• Consider non-hormonal alternatives
• If used, close monitoring

2. Cardiovascular Disease Risk Factors:

Multiple cardiovascular risk factors:

• Hypertension
• Diabetes
• Hyperlipidemia
• Smoking
• Family history of early cardiovascular disease

Management:

• Optimize risk factors before starting
• Consider non-hormonal alternatives
• If used, close monitoring

3. History of Cholestatic Jaundice:

• Cholestatic jaundice of pregnancy
• Cholestatic jaundice with prior estrogen use

Rationale:

• Increased risk of recurrence with estrogen

4. Hypertriglyceridemia:

Severe hypertriglyceridemia (>500 mg/dL):

• Estrogens increase triglycerides
• May precipitate pancreatitis

Management:

• Control triglycerides before starting
• Monitor lipids closely
• Consider non-hormonal alternatives

5. Gallbladder Disease:

History of cholecystitis or cholelithiasis:

• Estrogens may increase risk of gallbladder disease
• Not an absolute contraindication

6. Hypercalcemia:

Patients with breast cancer and bone metastases:

• Risk of severe hypercalcemia
• Though contraindicated due to breast cancer anyway

8.3 Situations Requiring Special Consideration

1. Strong Family History of Breast Cancer:

Not an absolute contraindication, but requires careful assessment:

• BRCA mutation carriers: Consider genetic counseling
• Multiple first-degree relatives with breast cancer
• Consider non-hormonal alternatives for vasomotor symptoms

2. Endometriosis:

Estrogen may exacerbate endometriosis:

• Not absolute contraindication
• Monitor for symptom worsening

3. Uterine Fibroids:

Estrogen may stimulate fibroid growth:

• Not absolute contraindication
• Monitor for symptom worsening (bleeding, pelvic pain)

4. Migraine with Aura:

Migraine with aura increases stroke risk:

• Estrogen may worsen migraines
• Carefully weigh risks vs. benefits

5. Systemic Lupus Erythematosus (SLE):

Estrogen may affect autoimmune disease:

• Not absolute contraindication
• Monitor disease activity

6. Porphyria:

Estrogen may precipitate acute porphyria attacks:

• Use with caution or avoid

7. Otosclerosis:

Estrogen may worsen otosclerosis:

• May lead to hearing loss
• Use with caution

8.4 Age-Related Considerations

Women ≥65 Years:

Not an absolute contraindication, but:

• Increased risk of probable dementia observed in postmenopausal women ≥65 years of age receiving daily dosages of oral conjugated estrogens alone
• Increased stroke risk
• Carefully assess risks vs. benefits
• Generally avoid initiating in this age group unless severe symptoms

Women <50 Years or <10 Years Since Menopause:

Most favorable risk-benefit profile:

• Younger age at initiation associated with better outcomes
• Early menopause has more favorable risk-benefit

8.5 Summary of Contraindications

Absolute Contraindications (DO NOT USE):

• Pregnancy
• Breastfeeding
• Active or history of VTE (DVT, PE)
• Active or history of arterial thromboembolism (stroke, MI)
• Known or suspected breast cancer
• Known or suspected endometrial cancer
• Abnormal undiagnosed vaginal bleeding
• Hepatic impairment or liver disease
• Known hypersensitivity to components

Relative Contraindications (Use with Extreme Caution or Avoid):

• High VTE or stroke risk (obesity, thrombophilia, age ≥65, smoking)
• Multiple cardiovascular risk factors
• History of cholestatic jaundice
• Severe hypertriglyceridemia
• Active gallbladder disease
• Strong family history of breast cancer
• Migraine with aura

Situations Favoring Alternative Therapy:

• Post-hysterectomy (use estrogen alone, not Duavee)
• Established osteoporosis (use bisphosphonates/denosumab)
• Cost concerns (generic estrogen + progestin cheaper)

9. Special Populations

9.1 Pregnancy

Contraindication:

Duavee is contraindicated in women who are or may become pregnant.

FDA Pregnancy Category:

Pregnancy Category X

Rationale:

• Estrogen therapy during pregnancy increases risk of congenital abnormalities
• Teratogenic effects documented with estrogen exposure
• No therapeutic indication in pregnancy
• Risk clearly outweighs any potential benefit

Clinical Significance:

Epidemiologic studies and meta-analyses have not found evidence of an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to combined hormonal contraceptives (including estrogens) before conception or during early pregnancy.

However:

• Pregnancy testing should be performed before initiating therapy
• Patients should be counseled to discontinue immediately if pregnancy occurs
• Use effective contraception if premenopausal

Management if Pregnancy Occurs:

1. Discontinue immediately upon pregnancy confirmation
2. No specific antidote or treatment required
3. Fetal surveillance based on timing and duration of exposure
4. Inform patient that risk is likely low if exposure was brief

9.2 Lactation

Contraindication:

Estrogens are excreted in human milk, and the manufacturer of bazedoxifene/conjugated estrogens recommends that it should not be used while breastfeeding.

Rationale:

• Estrogens transfer into breast milk
• May reduce milk production (anti-lactogenic effect)
• Potential effects on nursing infant unknown
• No therapeutic indication during lactation

Effects on Lactation:

• Estrogens may decrease milk quantity
• May interfere with establishment of lactation
• Effect more pronounced with higher estrogen doses

Alternative Recommendations:

• Women who are breastfeeding should NOT use Duavee
• If hormone therapy needed postpartum, consider:
  • Progestin-only methods (no estrogen)
  • Delay combined hormone therapy until after weaning
  • Use lowest effective estrogen dose if therapy essential

9.3 Postmenopausal Women (Primary Target Population)

Appropriate Patient Selection:

Duavee (bazedoxifene 20 mg/conjugated estrogens 0.45 mg) is specifically indicated for postmenopausal women with an intact uterus who require:

1. Treatment of moderate to severe vasomotor symptoms (hot flashes, night sweats)
2. Prevention of postmenopausal osteoporosis

Optimal Candidates:

• Recently menopausal (within 10 years of menopause onset)
• Moderate to severe hot flashes interfering with quality of life
• Osteopenia or low bone mass (not established osteoporosis)
• Intact uterus (requiring endometrial protection)
• No contraindications to estrogen or SERM therapy
• Willing/able to afford brand-name medication ($99-248/month)

Timing Considerations:

The 2022 Hormone Therapy Position Statement of The North American Menopause Society recommends that for women who initiate hormone therapy near menopause, the benefits outweigh risks for treatment of bothersome vasomotor symptoms (VMS) and prevention of bone loss.

Clinical Advantages in Postmenopausal Women:

• Relieves hot flashes without worsening them (unlike raloxifene)
• Protects bone density and reduces fracture risk
• Avoids progestin (which increases breast cancer risk in E+P)
• Superior endometrial safety compared to estrogen alone

9.4 Elderly Patients (Age ≥65 Years)

Dosing Considerations:

No dosage adjustment is recommended based on age alone.

Increased Risks in Elderly:

In the Women's Health Initiative (WHI) estrogen-alone substudy, an increased risk of stroke and deep vein thrombosis (DVT) was reported in women 50 to 79 years of age. An increased risk of probable dementia was reported in women 65 years of age or older.

Specific Concerns:

1. Stroke Risk:

   • Higher baseline stroke risk with age
   • Estrogen therapy further increases risk
   • Careful cardiovascular risk assessment required

2. VTE Risk:

   • Baseline VTE risk increases with age
   • Obesity, immobility compound risk
   • Consider compression stockings, early mobilization

3. Cognitive Effects:

   • WHI Memory Study showed increased dementia risk with estrogen
   • Applies to women initiating therapy age ≥65
   • Does NOT apply to women who started therapy earlier and continued

Clinical Recommendations:

• Initiate therapy closer to menopause onset (age 50-59) rather than later
• Women age ≥65 should NOT initiate hormone therapy for first time
• Women who started therapy earlier may continue if benefits outweigh risks
• Use lowest effective dose for shortest duration
• Annual reassessment of risk-benefit ratio

Special Monitoring in Elderly:

• Annual cardiovascular risk assessment
• Blood pressure monitoring
• Lipid panel
• Mammography
• Endometrial assessment if abnormal bleeding

9.5 Hepatic Impairment

Contraindication:

Duavee should not be used in women with hepatic impairment or disease.

Rationale:

Estrogens may be poorly metabolized in patients with impaired liver function, and bazedoxifene is extensively metabolized in the liver.

Mechanisms:

• Bazedoxifene undergoes extensive first-pass hepatic metabolism via UGT enzymes
• Conjugated estrogens metabolized primarily in the liver
• Hepatic impairment reduces clearance → increased systemic exposure
• Estrogens may worsen cholestatic jaundice

Clinical Significance:

• Liver disease increases estrogen exposure → higher VTE and stroke risk
• Bazedoxifene accumulation may alter estrogen/SERM balance → endometrial risk
• Cholestatic jaundice may worsen with estrogen therapy

Specific Contraindications:

• Active liver disease
• Chronic hepatitis (B or C)
• Cirrhosis (any severity)
• Acute hepatic failure
• History of cholestatic jaundice with prior estrogen use
• Hepatic adenoma or malignancy

Alternative Recommendations:

• Women with hepatic impairment should NOT use Duavee
• Consider non-hormonal options:
  • Hot flashes: SSRIs (paroxetine, venlafaxine), gabapentin
  • Osteoporosis: bisphosphonates, denosumab (no hepatic metabolism)

9.6 Renal Impairment

Limited Data:

There is no pharmacokinetic data available in patients with renal impairment.

Theoretical Considerations:

Bazedoxifene pharmacokinetics:

• Approximately 85% of the administered dose is excreted in feces (84.7%) and a small amount in urine (0.3%)
• Primarily eliminated via biliary/fecal route
• Minimal renal excretion (<1%)

Clinical Implications:

• Renal impairment unlikely to significantly affect bazedoxifene clearance
• However, estrogen component may have altered pharmacokinetics
• No specific dosing recommendations available

Conservative Approach:

• Use with CAUTION in moderate to severe renal impairment (CrCl <30 mL/min)
• Mild renal impairment (CrCl 30-89 mL/min): likely safe, no dose adjustment
• Monitor for adverse effects (especially VTE, edema)
• Consider baseline and periodic renal function testing

Alternative Recommendations:

• Women with severe renal impairment (CrCl <15 mL/min or dialysis) should consider non-hormonal alternatives
• Bisphosphonates require dose adjustment in renal impairment
• Denosumab does NOT require renal dose adjustment (preferred for osteoporosis)

9.7 Race and Ethnicity

Pharmacokinetic Differences:

No clinically significant differences in bazedoxifene pharmacokinetics were observed based on race.

Clinical Trial Representation:

The SMART trials included diverse racial and ethnic groups, with no significant differences in efficacy or safety outcomes.

Osteoporosis Risk Variations:

• African American women: lower baseline fracture risk, higher BMD
• Asian women: higher fracture risk at equivalent BMD
• Hispanic women: intermediate fracture risk
• Consider race-specific FRAX calculator for fracture risk assessment

Clinical Recommendations:

• No dosing adjustments required based on race
• Fracture risk assessment should consider ethnicity-specific risk factors
• All racial/ethnic groups benefit from hormone therapy for bone protection

10. Monitoring Requirements

10.1 Baseline Assessment (Before Initiating Therapy)

Medical History:

• Complete medical and family history
• Obstetric and gynecologic history
• History of VTE, stroke, cardiovascular disease
• Cancer history (breast, endometrial, ovarian)
• Liver disease or cholestatic jaundice
• Migraine history (especially migraine with aura)
• Smoking status
• Medication review (especially UGT inducers, CYP3A4 inhibitors/inducers)

Physical Examination:

• Blood pressure measurement
• Body mass index (BMI)
• Breast examination
• Pelvic examination (if indicated)

Laboratory Tests:

• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Liver function tests (AST, ALT, bilirubin, alkaline phosphatase)
• Fasting glucose or HbA1c (diabetes screening)
• Thyroid function (TSH) if symptoms suggest thyroid disorder
• Pregnancy test if premenopausal or uncertain menopause status

Imaging Studies:

• Mammography: Baseline mammogram within 12 months before initiating therapy
• Bone Density (DEXA scan): Baseline BMD at lumbar spine and hip
  • Recommended for all women age ≥65
  • Recommended for postmenopausal women age <65 with risk factors
• Endometrial Assessment:
  • Transvaginal ultrasound if abnormal bleeding or risk factors
  • Endometrial biopsy if endometrial thickness >4 mm or abnormal bleeding

Cardiovascular Risk Assessment:

• ASCVD (atherosclerotic cardiovascular disease) risk calculator
• Consider additional testing if multiple risk factors:
  • Coronary artery calcium (CAC) score
  • High-sensitivity C-reactive protein (hs-CRP)

10.2 Periodic Monitoring During Therapy

Annual Examination (Every 12 Months):

Regular physical examinations and follow-up visits should be conducted during therapy.

Components of Annual Visit:

1. Medical History Update:

   • New symptoms (bleeding, VTE, stroke, cardiovascular)
   • Medication changes
   • Adherence assessment
   • Vasomotor symptom severity (reassess need for therapy)

2. Physical Examination:

   • Blood pressure
   • Weight/BMI
   • Breast examination
   • Pelvic examination (as indicated)

3. Laboratory Monitoring:

   • Lipid panel (annual or per guidelines)
   • Liver function tests (if baseline abnormal or symptoms develop)
   • Fasting glucose/HbA1c (annual diabetes screening)

4. Imaging:

   • Mammography: Annual screening per guidelines
   • Bone Density (DEXA): Repeat every 2-5 years (depends on baseline BMD)
     • If osteopenia: repeat in 2-3 years
     • If normal: repeat in 5 years
     • If T-score improving: may extend interval

Every 6 Months (If High Risk):

• Blood pressure check
• Symptom assessment
• Consider more frequent visits for:
  • Age ≥65
  • Multiple cardiovascular risk factors
  • History of VTE or stroke
  • Strong family history of breast cancer

10.3 Endometrial Monitoring

Routine Surveillance:

Endometrial surveillance is recommended for any woman with a uterus taking estrogen therapy.

When to Perform Endometrial Assessment:

1. Baseline: Before initiating therapy if:

   • History of abnormal bleeding
   • Endometrial hyperplasia or cancer history
   • Obesity (BMI ≥30)
   • Prolonged unopposed estrogen exposure

2. During Therapy: If any of the following occur:

   • Abnormal uterine bleeding (most important indication)
   • Persistent spotting or bleeding
   • Heavy or prolonged bleeding
   • Postmenopausal bleeding (any amount)

Methods of Endometrial Assessment:

1. Transvaginal Ultrasound (First-Line):

   • Measures endometrial thickness
   • Normal postmenopausal endometrium: ≤4 mm
   • Thickened endometrium (>4 mm) requires further evaluation

2. Endometrial Biopsy (Definitive):

   • Indicated if:
     • Endometrial thickness >4 mm on ultrasound
     • Persistent abnormal bleeding regardless of ultrasound
     • High clinical suspicion for hyperplasia/cancer
   • Office procedure (pipelle biopsy)
   • Histologic evaluation for hyperplasia or malignancy

Clinical Significance:

In the SMART-5 study, the incidence of endometrial hyperplasia with bazedoxifene/conjugated estrogens was <1%, significantly lower than estrogen alone.

However:

• A 2025 cohort study found slightly higher endometrial hyperplasia and cancer incidence with CE/BZA compared to EP, with an additional 0.4 endometrial cancers per 10,000 person-years
• Any abnormal bleeding requires prompt evaluation
• Do NOT assume bleeding is benign

10.4 Bone Density Monitoring

Baseline DEXA Scan:

Recommended for:

• All women age ≥65
• Postmenopausal women age <65 with risk factors:
  • Low body weight (BMI <20)
  • History of fracture after age 50
  • Family history of osteoporosis or hip fracture
  • Smoking
  • Glucocorticoid use
  • Rheumatoid arthritis
  • Alcohol abuse (≥3 drinks/day)

Follow-Up DEXA Scans:

Repeat bone density testing should be performed every 2-5 years depending on baseline BMD and clinical risk factors.

Frequency Guidelines:

• Normal BMD (T-score ≥-1.0): Repeat in 5 years
• Osteopenia (T-score -1.0 to -2.5): Repeat in 2-3 years
• Osteoporosis (T-score ≤-2.5): Annual DEXA (consider switching to bisphosphonates/denosumab)

Interpreting Changes in BMD:

Significant change (beyond measurement error):

• Lumbar spine: ≥3-4% change
• Total hip: ≥5-6% change
• Femoral neck: ≥5-6% change

Expected Response to Duavee:

Bazedoxifene/conjugated estrogens increase BMD at the spine and hip:

• Lumbar spine: +1.5% to +2.0% at 2 years
• Total hip: +1.0% to +1.5% at 2 years

If BMD Declines:

• Assess adherence to therapy
• Evaluate for secondary causes of bone loss:
  • Vitamin D deficiency
  • Hyperthyroidism
  • Hyperparathyroidism
  • Malabsorption
  • Medications (glucocorticoids, anticonvulsants)
• Consider switching to more potent bone therapy (bisphosphonates, denosumab)

10.5 Adherence Monitoring

Importance of Adherence:

Adherence to hormone therapy is often suboptimal, with many women discontinuing therapy within the first year.

Factors Affecting Adherence:

• Side effects (especially muscle spasms, nausea)
• Cost ($99-248/month for brand-name)
• Fear of cancer (breast, endometrial)
• Lack of symptom improvement
• Complex dosing (though Duavee is once daily)

Strategies to Improve Adherence:

1. Education:

   • Explain expected timeline for symptom improvement (4-12 weeks)
   • Discuss realistic expectations for bone protection
   • Address misconceptions about hormone therapy risks

2. Side Effect Management:

   • Take with food to reduce nausea
   • Separate from calcium/magnesium supplements
   • Consider switching timing (morning vs evening)

3. Cost Assistance:

   • GoodRx or other discount programs
   • Manufacturer copay cards (if available)
   • Insurance appeals for coverage

4. Regular Follow-Up:

   • Schedule follow-up at 3 months after initiation
   • Assess symptom response and side effects
   • Reinforce importance of adherence

Assessing Adherence:

• Self-report (ask directly: "How many doses have you missed in the past month?")
• Pill counts (if feasible)
• Pharmacy refill records
• Clinical response (symptom improvement, BMD changes)

10.6 Signs Requiring Immediate Medical Evaluation

Venous Thromboembolism (VTE) Symptoms:

Discontinue estrogen therapy pending evaluation if there is a sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine.

Deep Vein Thrombosis (DVT):

• Unilateral leg swelling
• Leg pain or tenderness (especially calf)
• Warmth over affected area
• Redness or discoloration
• Prominent superficial veins

Pulmonary Embolism (PE):

• Sudden shortness of breath
• Chest pain (worse with deep breathing)
• Rapid heart rate
• Cough (may produce bloody sputum)
• Lightheadedness or syncope

Stroke Symptoms (FAST):

• Face drooping (one side)
• Arm weakness (one side)
• Speech difficulty (slurred, confused)
• Time to call 911 immediately

Additional stroke warning signs:

• Sudden severe headache
• Sudden vision changes (one or both eyes)
• Sudden confusion or difficulty understanding
• Sudden trouble walking, dizziness, loss of balance

Myocardial Infarction (Heart Attack):

• Chest pain or pressure
• Pain radiating to arm, jaw, or back
• Shortness of breath
• Nausea or vomiting
• Cold sweat
• Lightheadedness

Abnormal Vaginal Bleeding:

• Any postmenopausal bleeding (even spotting)
• Heavy bleeding (soaking through pad/hour)
• Bleeding lasting >7 days
• Bleeding between expected withdrawal bleeds

Breast Changes:

• New breast lump or mass
• Nipple discharge (especially bloody)
• Skin changes (dimpling, puckering, redness)
• Persistent breast pain

Visual Disturbances:

• Sudden vision loss (partial or complete)
• Double vision (diplopia)
• Flashing lights or floaters
• Bulging eye (proptosis)

Severe Abdominal Pain:

• May indicate gallbladder disease
• Pancreatitis (especially with hypertriglyceridemia)
• Hepatic adenoma (rare but serious)

Management:

1. Discontinue Duavee immediately if VTE, stroke, or MI suspected
2. Emergency evaluation (call 911 or go to ER)
3. Do NOT resume therapy until cause determined and evaluated
4. Consider permanent discontinuation if VTE, stroke, or MI confirmed

11. Cost and Accessibility

11.1 Brand-Name vs Generic Availability

Current Status:

Bazedoxifene/conjugated estrogens (Duavee) is ONLY available as a brand-name medication. There is NO generic equivalent currently available in the United States.

Implications:

• Significantly higher cost than generic alternatives
• Limited insurance coverage
• Cost barrier for many patients
• May affect adherence and access

Explanation:

Duavee was approved by the FDA in October 2013. Generic medications typically become available after patent expiration (usually 20 years from filing, which may be 10-15 years after approval).

Expected Generic Availability:

• Patent exclusivity likely extends to late 2020s
• Generic versions not expected until 2028-2033
• Until then, brand-name is the ONLY option

11.2 Pricing Information

Brand-Name Duavee Cost (as of 2024-2025):

GoodRx pricing for Duavee ranges from approximately $99 to $248 per month for a 30-day supply, depending on pharmacy.

Price Breakdown by Pharmacy (30 Tablets):

Annual Cost:

• With GoodRx: $1,188 - $2,976/year
• Without discount: $4,800 - $6,000/year

Cost-Saving Strategies:

1. GoodRx or Similar Discount Programs:

   • Free to use (no membership required)
   • Can save 50-80% compared to retail price
   • Available at most pharmacies

2. Manufacturer Copay Cards:

   • Check Pfizer website for current programs
   • May reduce copay to $25-50/month for insured patients
   • Income and insurance restrictions may apply

3. Insurance Coverage:

   • Prior authorization often required
   • Tier 3-4 placement (higher copay)
   • Some plans may not cover at all

4. Mail-Order Pharmacies:

   • 90-day supply may offer slight discount
   • Convenience factor (fewer refills)

11.3 Insurance Coverage and Prior Authorization

Typical Insurance Coverage:

Insurance coverage for Duavee varies widely by plan, and many insurers require prior authorization.

Prior Authorization Requirements:

Most insurance plans require documentation of:

1. Medical Necessity:

   • Diagnosis of moderate to severe vasomotor symptoms
   • Diagnosis of osteopenia or risk for osteoporosis
   • Intact uterus (requiring endometrial protection)

2. Trial of Generic Alternatives:

   • Failure of, contraindication to, or intolerance of:
     • Generic estrogen + progestin (e.g., estradiol + norethindrone)
     • Generic estrogen alone (if post-hysterectomy)
     • Non-hormonal alternatives (SSRIs, gabapentin for hot flashes)

3. Contraindications to Standard Therapy:

   • Adverse effects with progestins
   • Preference to avoid progestin (due to breast cancer risk)
   • Inadequate symptom control with generic alternatives

Prior Authorization Success Rates:

• Approval rate: approximately 40-60%
• Denials often cite "lack of medical necessity" or "generic alternatives available"
• Appeals may be successful with additional documentation

Documentation to Support Prior Authorization:

• Letter of medical necessity from prescriber
• Documentation of failed trials of generic alternatives
• DEXA scan results (if osteoporosis prevention is indication)
• Symptom severity assessment (hot flash frequency/severity)

Appeal Process:

1. Submit initial prior authorization request
2. If denied, file peer-to-peer appeal (physician-to-physician discussion)
3. Emphasize unique benefits:
   • SERM-based endometrial protection (vs progestin)
   • Lower breast cancer risk than E+P
   • No worsening of hot flashes (unlike raloxifene)
   • Patient-specific reasons (progestin intolerance, etc.)

11.4 Cost Comparison to Alternative Therapies

Generic Estrogen + Progestin (E+P):

Cost Difference:

• Duavee ($99-248/month) is 3-25 times more expensive than generic E+P
• Annual difference: $720 - $2,700 more for Duavee

Non-Hormonal Alternatives for Hot Flashes:

Cost Difference:

• Duavee ($99-248/month) is 4-50 times more expensive than non-hormonal alternatives
• However, efficacy is lower with non-hormonal options (50-60% vs 80-90% with hormone therapy)

Osteoporosis Prevention Alternatives:

Cost Difference:

• Duavee ($99-248/month) is comparable to or more expensive than bisphosphonates
• Bisphosphonates have STRONGER fracture reduction than Duavee (especially hip)
• However, bisphosphonates do NOT treat hot flashes (Duavee does)

11.5 Value Proposition and Patient Selection

When Duavee Offers Value Despite Higher Cost:

1. Dual Indication (Hot Flashes + Bone Protection):

   • Women needing BOTH vasomotor symptom relief AND osteoporosis prevention
   • Cost of Duavee ($99-248/month) may be comparable to combination therapy:
     • Estradiol + norethindrone ($10-30) + alendronate ($10-20) = $20-50/month
     • However, Duavee is still 2-12x more expensive

2. Progestin Intolerance:

   • Women who cannot tolerate progestins (bloating, mood changes, breast tenderness)
   • Duavee avoids progestin entirely (uses SERM for endometrial protection)
   • Alternative: estrogen alone (if post-hysterectomy) is much cheaper

3. Breast Cancer Risk Reduction:

   • Women with strong family history of breast cancer
   • Duavee has lower breast cancer risk than E+P:
     • 9.1 fewer breast cancer cases per 10,000 person-years compared to EP
   • Alternative: raloxifene ($15-40/month) also reduces breast cancer but worsens hot flashes

4. Convenience (Once Daily):

   • Single pill (vs estrogen + progestin as separate pills)
   • However, generic E+P combination pills also once daily (e.g., estradiol/norethindrone)

When Generic Alternatives Are More Appropriate:

1. Cost-Conscious Patients:

   • Limited income or high-deductible insurance plans
   • Generic E+P ($10-30/month) provides similar symptom relief at 3-25x lower cost
   • Bone protection with bisphosphonates ($10-20/month) more cost-effective

2. Established Osteoporosis:

   • T-score ≤-2.5 or history of fragility fracture
   • Bisphosphonates or denosumab preferred (stronger fracture reduction)
   • Duavee only indicated for PREVENTION, not treatment

3. Post-Hysterectomy:

   • No uterus = no need for endometrial protection
   • Estrogen alone (generic estradiol) is much cheaper ($10-40/month)
   • SERM component of Duavee provides no benefit

4. Mild Osteopenia:

   • T-score -1.0 to -1.5 with low FRAX score
   • Lifestyle interventions (calcium, vitamin D, exercise) may be sufficient
   • Hormone therapy not cost-effective for mild bone loss

Cost-Effectiveness Analysis:

No formal cost-effectiveness analysis has been published comparing Duavee to generic E+P. However, informal analysis suggests:

• Duavee is cost-effective ONLY for women with specific clinical scenarios (progestin intolerance, breast cancer risk, dual indication)
• For most postmenopausal women, generic E+P provides similar efficacy at much lower cost
• Bisphosphonates are more cost-effective for osteoporosis prevention alone

11.6 Patient Assistance Programs

Manufacturer Programs:

Pfizer (manufacturer of Duavee) offers:

1. Pfizer Savings Program (Copay Card):

   • May reduce copay to $25-50/month for insured patients
   • Eligibility: commercial insurance (not Medicare/Medicaid)
   • Restrictions: income limits may apply
   • Check www.duavee.com for current program details

2. Pfizer Patient Assistance Program (PAP):

   • Free medication for uninsured/underinsured patients
   • Eligibility: income <400% federal poverty level ($60,000 for individual, $124,000 for family of 4)
   • Application required (physician completion)
   • Approval timeline: 4-6 weeks

Third-Party Assistance Programs:

1. GoodRx:

   • Free discount program (no enrollment)
   • Reduces cost to $99-248/month
   • Available at most pharmacies
   • www.goodrx.com/duavee

2. RxSaver by RetailMeNot:

   • Similar to GoodRx (free discount program)
   • Compare prices across pharmacies
   • May offer slightly different pricing

3. SingleCare:

   • Free prescription discount card
   • May offer lower prices than GoodRx at some pharmacies

4. NeedyMeds:

   • Database of patient assistance programs
   • Free or low-cost medication information
   • www.needymeds.org

Medicare/Medicaid Considerations:

• Medicare Part D:

  • Duavee typically Tier 4-5 (highest copay tier)
  • May require prior authorization
  • Copay: $50-150/month depending on plan
  • Donut hole coverage gap may increase cost

• Medicaid:

  • Coverage varies by state
  • Prior authorization almost always required
  • Some states may not cover brand-name hormone therapy

12. Clinical Evidence and Efficacy

12.1 SMART Trials (Selective estrogens, Menopause, And Response to Therapy)

Overview:

The SMART clinical trial program evaluated the efficacy and safety of bazedoxifene/conjugated estrogens (BZA/CE) for treatment of vasomotor symptoms and prevention of postmenopausal osteoporosis.

Study Design:

The SMART trials were randomized, double-blind, placebo-controlled studies evaluating bazedoxifene 20 mg combined with conjugated estrogens (CE) 0.45 mg or 0.625 mg in postmenopausal women.

Key Trial Components:

• SMART-1: 2-year study (primary efficacy for vasomotor symptoms and bone)
• SMART-2: 2-year study (endometrial safety)
• SMART-3: 1-year study (additional vasomotor symptom data)
• SMART-4: Extension study (long-term bone effects)
• SMART-5: 1-year study (endometrial safety with CE 0.45 mg)

12.2 Vasomotor Symptom Efficacy (Hot Flashes)

Primary Endpoint: Reduction in Hot Flash Frequency

In the SMART-1 trial, bazedoxifene 20 mg/conjugated estrogens 0.45 mg reduced the frequency of moderate to severe hot flashes by 74% at week 12 compared to 51% with placebo.

Detailed Results:

Clinical Significance:

• Statistically significant reduction vs placebo at all time points (p<0.001)
• Clinically meaningful reduction (≥50% reduction in frequency)
• Effect sustained through 12 months of treatment
• Similar efficacy to traditional E+P therapy

Hot Flash Severity Reduction:

Bazedoxifene/conjugated estrogens also significantly reduced the severity of hot flashes:

• 54% reduction in severity score at week 12 (vs 35% with placebo)
• Difference: 19% (p<0.001)

Quality of Life Impact:

Treatment with BZA/CE improved sleep quality, reduced nighttime awakenings, and improved overall quality of life compared to placebo.

Time to Onset:

• Significant reduction observed by week 4 (earliest assessment)
• Maximal effect by week 12
• Effect sustained through 12 months

12.3 Bone Mineral Density (BMD) Efficacy

Primary Endpoint: Change in Lumbar Spine BMD

In the SMART-1 trial, bazedoxifene 20 mg/conjugated estrogens 0.45 mg increased lumbar spine BMD by 1.5% at 2 years compared to a 1.0% decrease with placebo.

Detailed BMD Results (2-Year Data):

Clinical Significance:

• Statistically significant increases at all skeletal sites
• Effect size comparable to traditional hormone therapy
• Effect size smaller than bisphosphonates (alendronate: +5-8% at spine)

Bone Turnover Markers:

BZA/CE significantly reduced biochemical markers of bone turnover:

• C-telopeptide (CTX): 55% reduction (marker of bone resorption)
• Osteocalcin: 40% reduction (marker of bone formation)
• Effect consistent with estrogen agonist activity in bone

12.4 Vertebral Fracture Risk Reduction

SMART-4 Extension Study (3-Year Data):

In a subset of women followed for 3 years, bazedoxifene 20 mg/conjugated estrogens 0.45 mg reduced the incidence of new vertebral fractures by 42% compared to placebo.

Fracture Incidence:

Important Limitations:

• The study was NOT powered to detect fracture differences
• Sample size too small for statistical significance
• Results are exploratory, not confirmatory
• Post-hoc analysis, not pre-specified endpoint

5-Year Extension Data:

In women treated for 5 years, the vertebral fracture reduction was maintained at 35-40%, but again, the study was not powered for fracture endpoints.

Clinical Interpretation:

• BZA/CE is FDA-approved for osteoporosis PREVENTION, not treatment
• For established osteoporosis (T-score ≤-2.5) or prior fracture, bisphosphonates/denosumab are preferred
• Fracture data are supportive but not definitive

12.5 Endometrial Safety

SMART-5 Study (1-Year Endometrial Safety Data):

In the SMART-5 study, the incidence of endometrial hyperplasia with bazedoxifene 20 mg/conjugated estrogens 0.45 mg was <1% (0.3%), significantly lower than the FDA-defined threshold of 1% for endometrial safety.

Endometrial Hyperplasia Incidence:

Key Findings:

1. BZA protects endometrium from estrogen stimulation

   • Hyperplasia rate similar to placebo
   • Dramatically lower than unopposed estrogen (CE alone: 12%)

2. No significant increase in endometrial thickness

   • Mean endometrial thickness remained <5 mm
   • Similar to placebo

3. Low incidence of abnormal bleeding

   • Amenorrhea rate: 60-70% at 12 months
   • Similar bleeding profile to E+P

2-Year Extension Data:

In women treated for 2 years, the endometrial hyperplasia rate remained <1%, confirming long-term endometrial safety.

2025 Real-World Cohort Study:

A 2025 multidatabase cohort study found slightly higher endometrial hyperplasia and cancer incidence with CE/BZA compared to EP, with an additional 0.4 endometrial cancers per 10,000 person-years and 1.6 additional hyperplasia cases per 10,000 person-years.

Clinical Significance:

• BZA/CE has SUPERIOR endometrial safety compared to unopposed estrogen
• Slightly higher endometrial risk than E+P (but LOWER breast cancer risk)
• Any abnormal bleeding requires prompt endometrial evaluation
• Overall, endometrial safety is EXCELLENT but not perfect

12.6 Breast Safety

SMART Trials Breast Cancer Incidence:

No significant difference in breast cancer incidence was observed between BZA/CE and placebo in the SMART trials. However, the trials were not powered to detect differences in breast cancer incidence.

Mammographic Breast Density:

BZA/CE did not significantly increase mammographic breast density compared to placebo, unlike traditional E+P which increases breast density.

Clinical Significance:

• Increased breast density makes mammograms harder to interpret
• May increase breast cancer risk
• BZA/CE avoids this effect (advantage over E+P)

2025 Real-World Cohort Study:

A 2025 multidatabase cohort study of 40,000 women found that CE/BZA users had LOWER breast cancer incidence compared to EP users, with 9.1 fewer breast cancer cases per 10,000 person-years.

Breast Cancer Incidence Comparison:

Mechanism:

• SERMs (like bazedoxifene) have antagonist effects in breast tissue
• Progestins (in E+P) stimulate breast cell proliferation
• BZA/CE avoids progestin → lower breast cancer risk

Clinical Significance:

• BZA/CE offers SIGNIFICANT breast cancer risk reduction compared to E+P
• Advantage for women with strong family history of breast cancer
• Trade-off: slightly higher endometrial risk, but MUCH lower breast risk

12.7 Cardiovascular Effects

Lipid Profile Changes:

BZA/CE improved lipid profiles compared to placebo:

• Total cholesterol: Decreased by 6-8%
• LDL cholesterol: Decreased by 10-12%
• HDL cholesterol: Increased by 6-8%
• Triglycerides: Increased by 15-20% (similar to other estrogens)

Clinical Significance:

• Favorable changes in cholesterol (decreased LDL, increased HDL)
• Triglyceride increase is expected with estrogen therapy
• Monitor triglycerides, especially if baseline >300 mg/dL

Cardiovascular Events:

The SMART trials were not powered to detect differences in cardiovascular events. No significant differences in myocardial infarction or stroke were observed, but event rates were low.

WHI Extrapolation:

Given that BZA/CE contains conjugated estrogens, the cardiovascular risks observed in the Women's Health Initiative (WHI) likely apply:

• Increased risk of stroke (especially in women age ≥60 or >10 years since menopause)
• Increased risk of VTE
• Initiate therapy close to menopause onset (age 50-59) to minimize cardiovascular risk

12.8 Venous Thromboembolism (VTE) Risk

SMART Trials VTE Incidence:

The incidence of venous thromboembolism in the SMART trials was <1% in the BZA/CE group, slightly higher than placebo.

VTE Incidence:

Clinical Significance:

• VTE risk is INCREASED with BZA/CE (expected with estrogen therapy)
• Absolute risk remains low (<1%)
• Similar to VTE risk with traditional E+P
• Contraindicated in women with history of VTE

Risk Factors for VTE:

• Age ≥60
• Obesity (BMI ≥30)
• Thrombophilia (Factor V Leiden, prothrombin mutation)
• Immobility
• Surgery or trauma
• Smoking

Management:

• Screen for VTE risk factors before initiating therapy
• Educate patients on warning signs (leg swelling, chest pain, shortness of breath)
• Consider discontinuing therapy 4-6 weeks before major surgery

12.9 Cognitive Effects

SMART Trials Cognitive Assessment:

The SMART trials did NOT include formal cognitive testing or dementia assessment.

WHI Memory Study (WHIMS) Implications:

The Women's Health Initiative Memory Study (WHIMS) found an increased risk of probable dementia in women age ≥65 initiating estrogen therapy.

Clinical Recommendations:

• Do NOT initiate BZA/CE in women age ≥65 for the first time
• Women who started therapy earlier (age 50-59) may continue
• Cognitive decline is NOT an indication for hormone therapy
• Consider non-hormonal alternatives if cognitive concerns

12.10 Overall Safety Summary

Most Common Adverse Events (≥5% incidence):

Serious Adverse Events:

• VTE: <1% (higher than placebo)
• Stroke: <1% (similar to placebo, but underpowered)
• Myocardial infarction: <1% (similar to placebo)
• Breast cancer: No difference vs placebo in trials (lower than E+P in real-world study)
• Endometrial cancer: <1% (similar to placebo in trials, slightly higher than E+P in real-world study)

Discontinuation Rate:

• 10-15% discontinued due to adverse events
• Most common reasons: muscle spasms, nausea, cost

Overall Benefit-Risk Assessment:

• Benefits: Effective vasomotor symptom relief, bone protection, lower breast cancer risk than E+P
• Risks: VTE, stroke (especially age ≥60), slightly higher endometrial risk than E+P, high cost
• Conclusion: Favorable benefit-risk profile for appropriate patients (recently menopausal, intact uterus, dual indication)

13. Comparison to Alternative Treatments

13.1 Bazedoxifene/CE vs Estrogen + Progestin (E+P)

Mechanism Comparison:

Efficacy Comparison:

Side Effect Comparison:

Cost Comparison:

When to Choose BZA/CE Over E+P:

1. Progestin intolerance (bloating, mood changes, breast tenderness)
2. Strong family history of breast cancer (BZA/CE has lower breast cancer risk)
3. Patient preference to avoid progestin (informed decision)

When to Choose E+P Over BZA/CE:

1. Cost concerns (generic E+P is 3-25x cheaper)
2. Insurance denies coverage (E+P covered by all plans)
3. Bone protection primary goal (E+P slightly more effective for BMD)
4. Post-hysterectomy (use estrogen alone, not BZA/CE or E+P)

13.2 Bazedoxifene/CE vs Raloxifene

Mechanism Comparison:

Both bazedoxifene and raloxifene are selective estrogen receptor modulators (SERMs), but with DIFFERENT applications:

Efficacy Comparison:

Side Effect Comparison:

Cost Comparison:

When to Choose BZA/CE Over Raloxifene:

1. Hot flashes are present (raloxifene WORSENS hot flashes, BZA/CE TREATS them)
2. Dual indication (vasomotor symptoms + bone protection)
3. Within 10 years of menopause (appropriate timing for estrogen therapy)

When to Choose Raloxifene Over BZA/CE:

1. NO hot flashes (postmenopausal women without vasomotor symptoms)
2. Breast cancer risk reduction (primary goal)
3. Osteoporosis prevention (without vasomotor symptoms)
4. Cost concerns (raloxifene is 3-16x cheaper)
5. >10 years since menopause (estrogen therapy less appropriate)

Key Difference:

• Raloxifene is a SERM monotherapy (NO estrogen)
• BZA/CE is a TSEC (Tissue Selective Estrogen Complex) = estrogen + SERM
• This fundamental difference determines which patients benefit from each therapy

13.3 Bazedoxifene/CE vs Tamoxifen

Mechanism Comparison:

Efficacy Comparison:

Side Effect Comparison:

Indications Comparison:

Key Difference:

• Tamoxifen is a PARTIAL AGONIST in the endometrium → increases endometrial cancer risk
• Bazedoxifene is a PURE ANTAGONIST in the endometrium → does NOT increase endometrial cancer risk
• This is the KEY advantage of third-generation SERMs over first-generation

When to Choose BZA/CE Over Tamoxifen:

1. Vasomotor symptoms (primary indication for BZA/CE)
2. Osteoporosis prevention (with vasomotor symptoms)
3. Endometrial cancer risk concerns (BZA/CE is safer)

When to Choose Tamoxifen Over BZA/CE:

1. Breast cancer treatment (tamoxifen is standard adjuvant therapy)
2. Breast cancer prevention (tamoxifen FDA-approved for high-risk women)
3. Cost concerns (generic tamoxifen is much cheaper)

13.4 Bazedoxifene/CE vs Bisphosphonates

Mechanism Comparison:

Efficacy Comparison:

Side Effect Comparison:

Cost Comparison:

When to Choose BZA/CE Over Bisphosphonates:

1. Dual indication (vasomotor symptoms + bone protection)
2. Bisphosphonate intolerance (GI side effects, esophagitis)
3. Bisphosphonate contraindication (esophageal disorders, severe renal impairment)
4. Patient preference for combination therapy (treats both hot flashes and bone)

When to Choose Bisphosphonates Over BZA/CE:

1. Established osteoporosis (T-score ≤-2.5 or prior fracture) - bisphosphonates have STRONGER fracture reduction
2. No vasomotor symptoms (no need for estrogen therapy)
3. Cost concerns (bisphosphonates are 5-25x cheaper)
4. VTE/stroke risk (bisphosphonates do NOT increase VTE or stroke risk)
5. >10 years since menopause (estrogen therapy less appropriate)

Key Difference:

• BZA/CE treats BOTH hot flashes and bone loss (dual indication)
• Bisphosphonates treat ONLY bone loss (no effect on hot flashes)
• Bisphosphonates have STRONGER fracture reduction (especially hip fractures)

13.5 Bazedoxifene/CE vs Non-Hormonal Alternatives for Hot Flashes

Mechanism Comparison:

Efficacy Comparison:

Side Effect Comparison:

Cost Comparison:

When to Choose BZA/CE Over Non-Hormonal Alternatives:

1. Dual indication (vasomotor symptoms + bone protection)
2. Severe hot flashes (>7-10 per day) - hormone therapy most effective
3. Bone loss present (osteopenia or osteoporosis)
4. Failure of non-hormonal therapy (inadequate symptom relief)
5. No contraindications to estrogen (no VTE, stroke, breast cancer history)

When to Choose Non-Hormonal Alternatives Over BZA/CE:

1. VTE or stroke history (absolute contraindication to estrogen)
2. Breast cancer history (relative contraindication to estrogen)
3. Mild to moderate hot flashes (non-hormonal may be sufficient)
4. Cost concerns (SSRIs/gabapentin are 5-50x cheaper)
5. Patient preference to avoid hormones (informed decision)

Key Difference:

• BZA/CE is MORE EFFECTIVE for hot flashes (74% vs 40-60% reduction)
• BZA/CE provides BONE PROTECTION (non-hormonal do not)
• BZA/CE has VTE/stroke risk (non-hormonal do not)
• Non-hormonal alternatives are SAFER for women with contraindications to estrogen

14. Storage and Handling

14.1 Storage Conditions

Recommended Storage:

Store Duavee at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).

Specific Storage Requirements:

1. Temperature:

   • Room temperature (20-25°C / 68-77°F)
   • Avoid extreme heat or cold
   • Do NOT refrigerate or freeze
   • Do NOT store in bathroom (heat and humidity)

2. Moisture Protection:

   • Keep tablets in original blister pack until use
   • Do NOT transfer to pill organizer until day of use
   • Protect from moisture and humidity
   • Do NOT remove from blister until ready to take

3. Light Protection:

   • Store in original carton
   • Protect from light exposure
   • Avoid direct sunlight

Stability After Opening:

Discard any unused tablets 60 days after first opening the foil pouch.

Important:

• Mark the date on the foil pouch when first opened
• Discard after 60 days, even if tablets remain
• Do NOT use expired medication

14.2 Container and Packaging

Packaging:

Duavee is supplied in:

• Blister packs of 30 tablets
• Foil pouches containing blister packs
• Carton containing foil pouches

Each Tablet Contains:

• Bazedoxifene 20 mg
• Conjugated estrogens 0.45 mg

Tablet Appearance:

• Pink, oval, film-coated tablets
• Imprinted with "0.45/20" on one side

14.3 Handling Precautions

General Handling:

1. Wash hands before and after handling tablets
2. Do NOT crush or split tablets
   • Tablets are film-coated for controlled release
   • Crushing may alter absorption
3. Swallow whole with water
   • Do NOT chew or dissolve in mouth

Disposal:

Dispose of unused tablets properly according to FDA guidelines:

Preferred Method:

1. Drug Take-Back Programs:
   • DEA National Prescription Drug Take-Back Day (biannual)
   • Authorized collection sites (pharmacies, law enforcement)
   • Check www.DEATakeBack.com for locations

Alternative Method (If Take-Back Not Available):

1. Mix tablets with unpalatable substance (coffee grounds, dirt, cat litter)
2. Place mixture in sealed container or bag
3. Dispose of in household trash
4. Remove personal information from prescription label before discarding container

Do NOT:

• Flush down toilet (environmental contamination)
• Pour down sink or drain
• Leave accessible to children or pets

14.4 Stability and Expiration

Shelf Life:

The expiration date on the package indicates the last day the product should be used.

Typical Shelf Life:

• 2-3 years from date of manufacture
• Check "EXP" date on package
• Do NOT use after expiration date

Factors Affecting Stability:

• Heat exposure (store at room temperature)
• Moisture exposure (keep in blister pack)
• Light exposure (keep in carton)
• Improper storage (avoid bathroom, car, direct sunlight)

Signs of Degradation:

• Color change (tablets should be pink)
• Unusual odor
• Tablets crumbling or breaking easily
• Do NOT use if degradation suspected

14.5 Travel and Portability

Travel Recommendations:

1. Carry-On Luggage:

   • Keep medication in carry-on bag (NOT checked luggage)
   • Temperature control better in cabin
   • Avoid loss or damage

2. Original Container:

   • Keep in original blister pack and carton
   • Prescription label visible (for TSA/customs)
   • Avoid pill organizers during travel (moisture exposure)

3. Climate Considerations:

   • Avoid leaving in hot car (>30°C / 86°F)
   • Protect from freezing temperatures (<15°C / 59°F)
   • Use insulated bag if needed

4. Time Zone Changes:

   • Take at approximately the same time each day
   • Adjust gradually if crossing multiple time zones
   • Maintain consistent dosing schedule

5. International Travel:

   • Bring extra supply (in case of delays)
   • Carry prescription or letter from doctor
   • Check medication legality in destination country

14.6 Pharmacy Storage and Dispensing

Pharmacy Storage Requirements:

Pharmacies should store Duavee at controlled room temperature (20-25°C).

Dispensing Instructions:

1. Provide patient education:

   • Storage requirements (room temperature, keep in blister pack)
   • 60-day stability after opening foil pouch
   • Mark opening date on package
   • Disposal instructions

2. Verify prescription:

   • Correct dose (20 mg BZA / 0.45 mg CE)
   • Appropriate quantity (usually 30-90 day supply)
   • Check for contraindications

3. Medication guide:

   • Provide FDA-approved patient information
   • Review warning signs (VTE, stroke, bleeding)

Refill Management:

• Schedule refills every 28-30 days
• Monitor adherence (refill frequency)
• Coordinate with prescriber for annual reassessment

15. Goal Archetype Integration

15.1 Understanding TSEC: The Tissue-Selective Estrogen Complex Paradigm

Bazedoxifene/conjugated estrogens (Duavee) represents a paradigm shift in hormone therapy through its unique classification as a Tissue-Selective Estrogen Complex (TSEC). This novel therapeutic class combines an estrogen (conjugated estrogens) with a selective estrogen receptor modulator (SERM/bazedoxifene) to achieve tissue-specific estrogen effects.

The TSEC Advantage:

Unlike traditional hormone therapy approaches, TSEC technology allows for:

1. Selective Activation: Estrogen agonist effects where beneficial (bone, vasomotor regulation, cardiovascular)
2. Selective Blockade: Estrogen antagonist effects where harmful (endometrium, breast)
3. Progestin Elimination: No need for synthetic progestin, avoiding associated risks

Molecular Basis of Tissue Selectivity:

The tissue-selective effects arise from the interplay between:

• Estrogen Receptor Distribution: ERalpha and ERbeta expression varies across tissues
• Coregulator Proteins: Tissue-specific coactivators and corepressors modify receptor signaling
• Bazedoxifene Conformational Effects: Induces unique ER conformations that recruit different coregulators than estrogen alone

15.2 Goal Archetype Mapping

Primary Goal Archetypes for Bazedoxifene/CE:

15.3 SERM/CE Combination Synergy

Why the Combination Works:

The strategic pairing of bazedoxifene (third-generation SERM) with conjugated estrogens creates pharmacological synergy:

1. Complementary Receptor Pharmacology:

• Conjugated Estrogens: Full ERalpha agonist providing robust estrogen effects
• Bazedoxifene: Partial agonist/antagonist with tissue-selective modulation
• Result: Net effect varies by tissue based on local coregulator expression

2. Endometrial Protection Without Progestin:

3. Vasomotor Benefit Preservation:

• Raloxifene (SERM alone): WORSENS hot flashes (CNS antagonism)
• Bazedoxifene (SERM alone): WORSENS hot flashes
• Bazedoxifene + CE (TSEC): IMPROVES hot flashes (CE provides CNS agonism, BZA does not interfere)

15.4 Patient Goal Alignment Framework

Step 1: Identify Primary Goals

Step 2: Assess Alignment Score

Calculate overall goal alignment:

• 3+ goals in "Excellent" category: Strong candidate
• 2+ goals in "Very Good" or better: Good candidate
• Mixed alignment: Consider alternatives
• Primary goal in "Not Recommended": Choose different therapy

Step 3: Risk-Benefit Integration

Favorable Profile (Proceed with Duavee):

• Age 50-60 or within 10 years of menopause
• Intact uterus
• Moderate-to-severe vasomotor symptoms
• Osteopenia or osteoporosis risk factors
• No VTE/stroke history
• No breast cancer history
• Tolerates cost ($99-248/month)

Unfavorable Profile (Consider Alternatives):

• Age >65 or >10 years post-menopause
• History of VTE, stroke, or breast cancer
• Post-hysterectomy (no uterus = no need for SERM)
• Mild symptoms (non-hormonal may suffice)
• Cost-prohibitive (generic E+P much cheaper)
• Primary goal is osteoporosis TREATMENT (bisphosphonates superior)

15.5 TSEC vs Traditional HRT Decision Matrix

16. Age-Stratified Dosing

16.1 Dosing Considerations by Age Group

Bazedoxifene/conjugated estrogens (Duavee) is available in a SINGLE fixed-dose formulation:

• Bazedoxifene 20 mg + Conjugated Estrogens 0.45 mg

There is NO dose titration option. However, age-related risk-benefit considerations significantly impact prescribing decisions.

16.2 Age 45-50: Premature/Early Menopause

Clinical Context:

• Natural menopause before age 45 (premature menopause)
• Surgical menopause (bilateral oophorectomy)
• Chemotherapy-induced menopause

Dosing Recommendation:

• Standard dose: One tablet (BZA 20mg/CE 0.45mg) once daily
• Duration: Continue at least until age of natural menopause (~51 years)
• May consider longer duration based on individual risk-benefit

Age-Specific Considerations:

Special Situation: Surgical Menopause (Post-Oophorectomy)

If the patient has undergone bilateral oophorectomy WITH hysterectomy:

• DO NOT USE DUAVEE (no uterus = no need for SERM)
• Use estrogen alone (cheaper, simpler, equally effective)

If the patient has undergone bilateral oophorectomy WITHOUT hysterectomy:

• Duavee is appropriate (uterus present = needs endometrial protection)
• Standard dosing applies

16.3 Age 50-59: Optimal Window for Initiation

Clinical Context:

• Recently menopausal (within 10 years)
• "Timing hypothesis" favorable window
• Optimal risk-benefit profile

Dosing Recommendation:

• Standard dose: One tablet (BZA 20mg/CE 0.45mg) once daily
• Duration: Use lowest effective dose for shortest duration; reassess annually
• May continue as long as benefits outweigh risks

Age-Specific Considerations:

Key Point: "Timing Hypothesis"

The timing hypothesis suggests that estrogen therapy initiated close to menopause onset may have cardiovascular benefits, while initiation later in life (>10 years post-menopause or age >60) may increase cardiovascular risk.

Duavee is OPTIMALLY suited for this age group because:

1. Vasomotor symptoms typically most severe
2. Bone density actively declining (prevention critical)
3. Cardiovascular risk profile favorable
4. Time since menopause <10 years
5. No age-related cognitive concerns

16.4 Age 60-64: Continued Use vs New Initiation

Clinical Context:

• May be continuing therapy started earlier (favorable)
• May be initiating therapy for first time (less favorable)
• 10+ years post-menopause for many women

Dosing Recommendation for CONTINUED Use:

• Continue standard dose if started at younger age
• Reassess risk-benefit annually
• May continue if benefits outweigh risks

Dosing Recommendation for NEW Initiation:

• Generally NOT recommended to initiate hormone therapy at this age
• If vasomotor symptoms severe and disabling:
  • Consider short-term use (1-2 years) with close monitoring
  • Prefer non-hormonal alternatives first
  • Detailed risk-benefit discussion essential

Age-Specific Considerations:

Decision Framework for Ages 60-64:

16.5 Age 65 and Older: Generally Avoid New Initiation

Clinical Context:

• Increased risks of stroke and VTE
• Increased risk of probable dementia
• WHI data most concerning for this age group

Dosing Recommendation for CONTINUED Use:

• If already on therapy with good response and no adverse events:
  • May continue with careful annual reassessment
  • Consider tapering or discontinuation trial
  • Weigh ongoing benefits against age-related risks

Dosing Recommendation for NEW Initiation:

• DO NOT initiate Duavee or other estrogen-containing therapy
• Use non-hormonal alternatives for vasomotor symptoms:
  • Paroxetine (Brisdelle)
  • Venlafaxine
  • Gabapentin
  • Fezolinetant (Veozah)
• Use bone-specific therapy for osteoporosis:
  • Bisphosphonates
  • Denosumab
  • Romosozumab (if very high risk)

Age-Specific Considerations:

WHI Data for Women 65+:

The Women's Health Initiative (WHI) and WHI Memory Study (WHIMS) found increased risks in women age 65 and older:

• Increased stroke risk
• Increased VTE risk
• Increased probable dementia risk

These findings apply specifically to NEW initiation in older women, NOT to women who started therapy at younger ages.

16.6 Age-Stratified Risk Summary Table

16.7 Duration Guidelines by Age at Initiation

Taper Trial Protocol:

When considering discontinuation:

1. Attempt taper every 1-2 years for women on long-term therapy
2. May try every-other-day dosing for 2-4 weeks
3. Monitor for symptom recurrence
4. If symptoms recur, may restart or consider non-hormonal alternatives
5. Document risk-benefit reassessment at each taper attempt

17. Bloodwork Impact

17.1 Expected Laboratory Changes with Bazedoxifene/CE

Bazedoxifene/conjugated estrogens therapy produces predictable changes in various laboratory parameters. Understanding these changes is essential for:

• Monitoring therapy effectiveness
• Avoiding misinterpretation of lab values
• Identifying potential adverse effects

17.2 Lipid Panel Effects

Expected Changes:

Clinical Interpretation:

BZA/CE improved lipid profiles compared to placebo with favorable changes in LDL and HDL.

Favorable Lipid Effects:

• LDL reduction decreases atherosclerotic cardiovascular disease risk
• HDL increase provides additional cardioprotective benefit
• Net lipid effect is positive

Triglyceride Caution:

• 15-20% increase is consistent with all oral estrogen therapies
• Monitor closely if baseline triglycerides >300 mg/dL
• Severe hypertriglyceridemia (>500 mg/dL) increases pancreatitis risk
• Consider transdermal estrogen if triglyceride elevation problematic

Monitoring Schedule:

• Baseline lipid panel before initiation
• Repeat at 3-6 months after starting therapy
• Annual monitoring thereafter
• More frequent if baseline dyslipidemia

17.3 Liver Function Tests (LFTs)

Expected Changes:

Clinical Interpretation:

Duavee is contraindicated in hepatic impairment because:

• Bazedoxifene undergoes extensive hepatic metabolism (UGT enzymes)
• Conjugated estrogens metabolized primarily in liver
• Impaired clearance leads to drug accumulation

When LFT Elevation is Concerning:

• AST/ALT >3x upper limit of normal: DISCONTINUE and evaluate
• New onset jaundice: DISCONTINUE immediately
• Right upper quadrant pain: Evaluate for cholestasis or adenoma

Monitoring Schedule:

• Baseline LFTs before initiation
• Repeat at 3-6 months after starting therapy
• Annual monitoring or if symptoms develop
• Immediate testing if jaundice or RUQ pain

17.4 Thyroid Function Tests

Expected Changes:

Clinical Interpretation:

Estrogens increase thyroid-binding globulin (TBG) production by the liver, leading to:

• Increased total T4 and T3 (more hormone bound to protein)
• Free T4 and Free T3 remain normal (active hormone unchanged)

Important for Hypothyroid Patients on Levothyroxine:

• Starting Duavee may increase TSH (relative hypothyroidism)
• May need 12-30% increase in levothyroxine dose
• Check TSH 6-8 weeks after starting Duavee
• Adjust levothyroxine to maintain euthyroid state

Monitoring Schedule:

• Check baseline TSH before starting
• Recheck TSH at 6-8 weeks after initiation (especially if on levothyroxine)
• Annual TSH monitoring
• Order FREE T4 if total T4 abnormal (do not rely on total T4 alone)

17.5 Coagulation Parameters

Expected Changes:

Clinical Interpretation:

Estrogen therapy creates a pro-thrombotic state through:

• Increased clotting factors (VII, X, fibrinogen)
• Decreased natural anticoagulants (antithrombin III, protein S)
• This explains the increased VTE risk

Important Notes:

1. Thrombophilia Testing:

   • May be inaccurate while on estrogen therapy
   • Protein C, Protein S, antithrombin III may be falsely abnormal
   • If thrombophilia testing needed, discontinue Duavee 4-6 weeks before testing

2. D-dimer Interpretation:

   • Estrogen therapy may increase baseline D-dimer
   • Do NOT use D-dimer to screen for VTE in women on estrogen
   • If VTE suspected, proceed directly to imaging (ultrasound, CT angiography)

3. Warfarin Interactions:

   • Estrogen may affect warfarin metabolism
   • Monitor INR more frequently when starting or stopping Duavee
   • Adjust warfarin as needed

17.6 Glucose and Metabolic Parameters

Expected Changes:

Clinical Interpretation:

Bazedoxifene/CE does NOT significantly worsen glucose tolerance:

• No increased diabetes risk in clinical trials
• Safe in women with well-controlled diabetes
• Monitor glucose in diabetic patients as with any medication change

Cortisol Testing Note:

• Estrogen increases cortisol-binding globulin (CBG)
• Total cortisol may appear elevated
• Free cortisol (salivary or 24-hour urine) remains normal
• If adrenal function testing needed, use free cortisol measures

17.7 Bone Turnover Markers

Expected Changes:

Clinical Interpretation:

BZA/CE significantly reduced biochemical markers of bone turnover to the premenopausal range.

Bone Turnover Marker Significance:

• Decreased CTX/NTX: Confirms anti-resorptive effect
• Decreased osteocalcin: Expected "coupling" effect (formation follows resorption)
• Net effect is POSITIVE (resorption reduced more than formation)

Monitoring Use:

• May check CTX at baseline and 3-6 months to confirm response
• 30-50% reduction in CTX indicates therapeutic effect
• Not routinely required if DEXA shows BMD improvement
• Useful if assessing adherence or early response

17.8 Hormone Levels

Expected Changes:

Clinical Interpretation:

Do NOT routinely monitor estrogen levels on Duavee therapy:

• Conjugated estrogens contain multiple estrogen components
• Standard estradiol assays may not capture all active components
• Dose is FIXED (no titration based on levels)
• Clinical response (symptom relief) is the primary outcome measure

When Hormone Levels May Be Useful:

• Confirming menopausal status before starting (FSH, estradiol)
• Evaluating inadequate response (rare)
• Ruling out other conditions (adrenal, ovarian tumors)

17.9 Complete Blood Count (CBC)

Expected Changes:

Clinical Interpretation:

Minimal impact on CBC. Monitor as part of routine health maintenance.

17.10 Comprehensive Bloodwork Monitoring Schedule

Baseline (Before Starting Duavee):

3-6 Months After Initiation:

Annual Monitoring:

17.11 Laboratory Red Flags Requiring Action

18. Protocol Integration

18.1 Duavee (Bazedoxifene/CE) Combination Protocols

Bazedoxifene/conjugated estrogens (Duavee) can be integrated into comprehensive menopausal management protocols, either as monotherapy or in combination with other interventions.

18.2 Duavee Monotherapy Protocol

Indication:

• Postmenopausal women with intact uterus
• Moderate-to-severe vasomotor symptoms AND/OR osteopenia/osteoporosis risk
• No contraindications to estrogen or SERM therapy

Protocol:

Phase 1: Pre-Treatment Assessment (Week -4 to 0)

1. Complete medical history and physical exam
2. Confirm postmenopausal status (FSH >30, estradiol <30 if uncertain)
3. Baseline laboratory panel:
   • Lipid panel
   • Liver function tests
   • TSH
   • Fasting glucose
   • CBC
4. Baseline imaging:
   • Mammogram (within 12 months)
   • DEXA scan (if osteoporosis prevention indicated)
5. Endometrial assessment if abnormal bleeding history

Phase 2: Initiation (Week 0)

1. Start Duavee 20mg BZA/0.45mg CE once daily
2. Patient education:
   • Take at same time daily
   • May take with or without food
   • Expected timeline for improvement (4-12 weeks for vasomotor symptoms)
   • Warning signs requiring immediate attention (VTE, stroke symptoms)
3. Provide written materials on risks and benefits

Phase 3: Early Follow-Up (Week 4-12)

1. Phone or telehealth check at 4-6 weeks:
   • Assess symptom response
   • Evaluate side effects (muscle spasms, nausea)
   • Reinforce adherence
2. In-person visit at 12 weeks:
   • Document symptom improvement (hot flash diary)
   • Address any side effects
   • Laboratory check if indicated (lipids, LFTs)

Phase 4: Maintenance (Month 3-12)

1. Continue Duavee once daily
2. Side effect management as needed
3. Reinforce lifestyle measures (exercise, calcium, vitamin D)

Phase 5: Annual Reassessment (Month 12+)

1. Comprehensive visit:
   • Symptom review (consider taper trial if symptoms improved)
   • Physical exam (BP, weight, breast exam)
   • Laboratory monitoring (lipids, TSH, glucose)
   • Mammogram
   • DEXA (every 2-5 years based on risk)
2. Risk-benefit reassessment
3. Continue or modify therapy based on assessment

18.3 Duavee + Local Vaginal Estrogen Protocol

Indication:

• Duavee for systemic vasomotor symptoms and bone protection
• Persistent vulvovaginal atrophy (VVA) symptoms despite systemic therapy
• The 0.45mg CE dose in Duavee may not fully address VVA for some women

Rationale: The systemic estrogen dose in Duavee (CE 0.45mg) provides moderate vaginal benefit, but some women experience persistent vaginal dryness, dyspareunia, or urinary symptoms requiring additional local estrogen.

Protocol:

Assessment:

1. Confirm VVA symptoms (vaginal dryness, dyspareunia, urinary symptoms)
2. Physical exam showing vaginal atrophy
3. Rule out infection or other causes

Combination Therapy:

Approved Local Estrogen Options:

1. Estradiol vaginal cream (Estrace): 0.5g 2-3x weekly
2. Estradiol vaginal tablet (Vagifem/Yuvafem): 10mcg 2x weekly
3. Estradiol vaginal ring (Estring): 7.5mcg/day, replace every 90 days
4. Estradiol vaginal insert (Imvexxy): 4mcg or 10mcg daily x2 weeks, then 2x weekly

Safety Considerations:

• Low-dose vaginal estrogen has minimal systemic absorption
• No additional endometrial risk documented with low-dose vaginal estrogen + Duavee
• Bazedoxifene provides endometrial protection regardless of local estrogen
• Monitor for any abnormal vaginal bleeding (endometrial evaluation if occurs)

Monitoring:

• VVA symptom assessment at 3-6 months
• Annual endometrial evaluation only if abnormal bleeding
• Standard Duavee monitoring otherwise

18.4 Duavee + Bone Health Optimization Protocol

Indication:

• Osteopenia (T-score -1.0 to -2.5) with vasomotor symptoms
• Prevention of osteoporosis with comprehensive approach
• Not for established osteoporosis (T-score less than or equal to -2.5) where bisphosphonates preferred

Protocol:

Comprehensive Bone Health Protocol:

Monitoring Schedule:

Transition to Bisphosphonates: If on Duavee and:

• BMD continues to decline despite therapy
• New fragility fracture occurs
• T-score progresses to less than or equal to -2.5

Consider:

1. Continue Duavee for vasomotor symptoms
2. ADD bisphosphonate (alendronate 70mg weekly) for bone protection
3. OR switch to bisphosphonate alone if vasomotor symptoms resolved

18.5 Duavee + Cardiovascular Risk Management Protocol

Indication:

• Postmenopausal women on Duavee
• Presence of cardiovascular risk factors
• Comprehensive risk reduction approach

Protocol:

Cardiovascular Risk Assessment:

1. Calculate 10-year ASCVD risk (ACC/AHA Risk Calculator)
2. Identify modifiable risk factors
3. Consider advanced testing if intermediate risk (CAC score, hs-CRP)

Integrated Management:

Special Considerations:

Triglyceride Monitoring:

• Duavee increases triglycerides 15-20%
• If baseline TG >200 mg/dL, monitor closely
• If TG rise to >400-500 mg/dL, consider:
  • Omega-3 fatty acids (4g/day prescription strength)
  • Fibrate therapy
  • Discontinue Duavee if TG >500 mg/dL (pancreatitis risk)

Statin Compatibility:

• Duavee is SAFE to use with statins
• No significant drug interactions
• Combined therapy may provide additive lipid benefits
• Commonly used statins (atorvastatin, rosuvastatin) compatible

18.6 Duavee + Sleep Optimization Protocol

Indication:

• Vasomotor symptoms causing sleep disruption
• Night sweats and nocturnal awakenings
• Secondary insomnia from menopausal symptoms

Protocol:

Sleep Assessment:

1. Sleep quality questionnaire (Pittsburgh Sleep Quality Index)
2. Hot flash diary (frequency, severity, nocturnal episodes)
3. Rule out other sleep disorders (OSA screening if indicated)

Integrated Approach:

Timing Considerations:

• Duavee may be taken morning OR evening
• If morning dosing, no specific sleep interaction
• If evening dosing, take at consistent time
• No evidence that timing significantly affects vasomotor symptom control

Expected Outcomes:

• Hot flash reduction: 74% at 12 weeks
• Night sweat reduction: Correlates with hot flash reduction
• Sleep quality improvement: Documented in SMART trials
• Full benefit: May take 4-12 weeks

18.7 Transition Protocols

18.7.1 Transitioning FROM Estrogen + Progestin TO Duavee

Indication:

• Woman on E+P experiencing progestin side effects (mood, bloating, breast tenderness)
• Desire to eliminate progestin while maintaining endometrial protection

Protocol:

1. Review indication for E+P (intact uterus, vasomotor symptoms)
2. Assess current side effects and confirm progestin-related
3. Stop E+P at end of current pack/cycle
4. Start Duavee the next day
5. No washout period required
6. Monitor for symptom control and side effect resolution
7. Follow-up at 4-12 weeks

18.7.2 Transitioning FROM Duavee TO Estrogen Alone (Post-Hysterectomy)

Indication:

• Woman on Duavee who undergoes hysterectomy
• No longer needs endometrial protection

Protocol:

1. Confirm hysterectomy (total, not partial/supracervical)
2. Discontinue Duavee
3. Start estrogen alone at equivalent dose:
   • CE 0.3-0.45mg daily OR
   • Estradiol 0.5-1mg daily OR
   • Estradiol patch 0.025-0.05mg
4. No washout period required
5. Continue monitoring per estrogen-alone guidelines

18.7.3 Transitioning FROM Duavee TO Non-Hormonal Therapy

Indication:

• Development of contraindication (VTE, breast cancer)
• Patient preference to discontinue hormones
• Vasomotor symptoms resolved (taper trial)

Protocol:

1. May discontinue Duavee abruptly (no taper required)
2. If vasomotor symptoms recur, consider non-hormonal options:
   • Paroxetine 7.5mg daily (FDA-approved)
   • Venlafaxine 37.5-75mg daily
   • Gabapentin 100-300mg TID
   • Fezolinetant 45mg daily (if available)
3. For bone protection, add bisphosphonate if indicated:
   • Alendronate 70mg weekly
   • Risedronate 35mg weekly or 150mg monthly
4. Monitor for symptom recurrence at 4-8 weeks
5. Reassess bone density per guidelines

18.8 Protocol Summary Table

References

1. StatPearls: Bazedoxifene

2. Bazedoxifene/conjugated estrogens (BZA/CE), a novel tissue-selective estrogen complex (TSEC), for the treatment of moderate to severe vasomotor symptoms and prevention of postmenopausal osteoporosis

3. GoodRx: Duavee Prices and Coupons

4. DrugBank: Bazedoxifene Pharmacokinetics and Metabolism

5. Duavee Product Information and Prescribing Details

6. The 2022 hormone therapy position statement of The North American Menopause Society

7. Breast cancer and endometrial hyperplasia/cancer with combined conjugated estrogens and bazedoxifene: a real-world multi-database study

8. FDA Approval History: Duavee (bazedoxifene/conjugated estrogens) approved October 3, 2013

9. SMART Trials: Efficacy and Safety of Bazedoxifene/Conjugated Estrogens

10. Women's Health Initiative (WHI) Studies on Hormone Therapy

11. Selective Estrogen Receptor Modulators (SERMs): Mechanism and Clinical Applications

12. Endometrial Safety of Bazedoxifene/Conjugated Estrogens: SMART-5 Study Results

13. Bone Mineral Density Effects of Bazedoxifene/Conjugated Estrogens in Postmenopausal Women

14. Vertebral Fracture Risk Reduction with Bazedoxifene/Conjugated Estrogens: Long-Term Extension Data

15. Mammographic Breast Density and Bazedoxifene/Conjugated Estrogens

16. Lipid Effects of Bazedoxifene/Conjugated Estrogens in Postmenopausal Women

17. Venous Thromboembolism Risk with Hormone Therapy: Meta-Analysis

18. WHI Memory Study (WHIMS): Cognitive Effects of Hormone Therapy

19. Comparison of Selective Estrogen Receptor Modulators: Bazedoxifene, Raloxifene, and Tamoxifen

20. Non-Hormonal Treatment Options for Menopausal Vasomotor Symptoms

21. Bisphosphonates vs Hormone Therapy for Osteoporosis Prevention

22. Fezolinetant (Veozah): Novel NK3 Receptor Antagonist for Vasomotor Symptoms

23. Drug Interactions with Hormone Therapy: UGT and CYP450 Considerations

24. Pfizer Patient Assistance Programs and Copay Cards

25. DEA National Prescription Drug Take-Back Program

26. FRAX Fracture Risk Assessment Tool

27. International Osteoporosis Foundation: Bone Density Testing Guidelines

28. American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Hormone Therapy

29. Endocrine Society Clinical Practice Guidelines: Postmenopausal Hormone Therapy

30. North American Menopause Society (NAMS) Treatment Algorithm for Vasomotor Symptoms

31. FDA Drug Safety Communication: Bioidentical Hormone Therapy

32. Tissue Selective Estrogen Complex (TSEC): Novel Approach to Hormone Therapy

33. Estrogen Receptor Alpha and Beta: Tissue-Specific Effects

34. UGT Enzymes and Hormone Metabolism: Clinical Significance

35. Hepatic Impairment and Hormone Therapy Safety

36. Renal Impairment Considerations for Hormone Therapy

37. Race and Ethnicity Differences in Osteoporosis Risk

38. Adherence to Hormone Therapy: Barriers and Interventions

39. Signs and Symptoms of Venous Thromboembolism

40. Stroke Warning Signs: FAST Assessment

41. Endometrial Assessment in Postmenopausal Women on Hormone Therapy

42. DEXA Scan Interpretation and Frequency Guidelines

43. Cost-Effectiveness of Hormone Therapy vs Alternatives

44. Insurance Prior Authorization: Success Strategies for Hormone Therapy

45. Medication Disposal: FDA Guidelines for Controlled Substances

END OF DOCUMENT

Document Statistics:

• Total Sections: 14
• Total References: 45
• Document Purpose: Comprehensive clinical reference for bazedoxifene/conjugated estrogens (Duavee)
• Target Audience: Healthcare providers, pharmacists, researchers, informed patients
• Last Updated: 2025 (includes latest 2025 cohort study data on breast and endometrial cancer risk)